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Supervisory Professor: Juan Fueyo, M.D.

Targeted immunotherapy with recombinant, oncolytic adenoviruses is under
investigation for the treatment of cancer. Evidence indicates adenoviruses induce autophagy
that is required for oncolysis, but the molecular regulation of autophagy in infected cells
remains under investigation. Our data suggested the canonical pathway regulating starvationinduced autophagy was not implemented in adenovirus-induced autophagy; however,
adenovirus infection triggered phosphorylation of c-Jun N-terminal kinases (JNK) that was
essential for autophagy. Adenoviral replication within the host cell elicited JNK pathway
activation leading to B cell lymphoma-2 (Bcl-2) phosphorylation. JNK-dependent Bcl-2
phosphorylation stimulated the dissociation of Bcl-2/beclin 1 heterodimers, enabling beclin 1 to
initiate autophagy. Moreover, phosphorylation of both JNK and Bcl-2 was observed in human
glioma xenografts after infection with the oncolytic, tropism-enhanced Delta-24-RGD
adenovirus, which is currently under investigation in a clinical trial for the treatment of
recurring malignant gliomas. Contrary to starvation-induced autophagy, inhibiting adenovirusmediated autophagy requires genetic knock-out of both JNK1 and JNK2 isoforms, suggesting
these proteins have overlapping roles for regulating autophagy in infected cells. Therefore, we
report a unique mechanism for the regulation of adenovirus-mediated autophagy that differs
from the conventional paradigm.
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Adenoviruses are highly immunogenic; and thus, potentially useful vectors for
immunotherapeutic strategies. Importantly, autophagy promotes the presentation of self and
foreign antigens for activation of immune cells. Our data demonstrated for the first time that
adenoviral epitopes were presented at the surface of cells through JNK- and autophagydependent mechanisms. Rapamycin, a chemical activator of autophagy, was able to enhance
adenoviral antigen presentation. This investigation proposes JNK signaling and autophagy
promote adenoviral antigen presentation to the immune system which can be leveraged in
developing recombinant adenoviruses for the advancement of anti-tumor immunotherapy. With
this knowledge, we developed a novel adenovirus expressing the immunogenic, tumor-specific
epidermal growth factor receptor variant III (EGFRvIII) peptide inserted in the adenoviral fiber
protein. We confirmed that the EGFRvIII epitope was displayed at the surface of cells in an
autophagy-dependent manner that could be enhanced by the pro-inflammatory cytokine,
interferon gamma. Thus, we established a new mechanism for the regulation of adenovirusmediated autophagy and antigen presentation that we employed for the advancement of
adenovirus-based vaccines.
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Chapter I: Background and Significance

Adenoviruses
Adenoviruses, otherwise known as the common cold, were discovered in the 1950s
upon being isolated from adenoid tissue (Rowe et al., 1953). They are the largest nonenveloped DNA virus, composed of an icosahedral capsid encompassing a linear, nonsegmented double stranded DNA genome. There are 51 different serotypes of adenovirus in the
family Adenoviridae (Russell, 2009). Adenoviruses attach to the host cell through interaction
between the knob domain of the adenoviral fiber and the coxsackie adenovirus receptor (CAR)
on the cell surface (Roelvink et al., 1998). The adenoviral penton bases in the capsid then
promote internalization through interaction with αv integrins (Figure 1A) (Wickham et al.,
1993). Once inside the cell, the viral DNA is transported to the cell nucleus for replication and
transcription of viral RNA.
Depending on the class and serotype, the size of the DNA genome can be between 26
and 45 thousand base pairs (Kpb) in length (Russell, 2009). The genome for one of the most
well-described serotypes, adenovirus class C serotype 5 (Ad5), is approximately 36 Kbp
(Chroboczek et al., 1992). The Ad5 genome is made up of four early genes (E1-E4) and five
late genes (L1-L5) (Figure 1B). The early genes are primarily involved in regulating adenovirus
replication and controlling the host cell functions, while the late genes include structural
proteins required for assembly. For example, the first protein expressed is early 1 A (E1A)
which is required for transcription of the viral DNA; and thus, required for viral replication and
production as well as counteracting antiviral cellular processes (Nevins et al., 1979; Bayley and
Mymryk, 1994). Conversely, the structural proteins hexon and fiber are encoded by L3 and L5
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Figure 1. The adenovirus structure and genome. A, It is a non-enveloped virus; the coat is
made up of numerous proteins. The fiber protein assists the virus to enter the cell via the
coxsackie adenovirus receptor. The penton base interacts with integrins for internalization of
the virus. B, Adenoviruses have a linear, double stranded DNA genome. The first gene
expressed is E1A, followed by all the early genes (E1B-E4, L1) required for adenoviral
replication and manipulation of particular cellular processes. The late genes (L1-L5) are mainly
involved in assembly.
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genes, respectively (Russell, 2009). The early gene transcripts can be detected in the cell within
a few hours; however, the entire adenoviral reproductive cycle is about 36 hours (Challberg
and Kelly, 1979; Nevins et al., 1979). Upon assembly, adenoviruses express the adenovirus
death protein (E3-11.6K) in order to lyse the cells allowing for their release and dissemination
(Tollefson et al., 1996).

Adenoviruses and cancer
Adenoviruses have been investigated for their potential as anti-cancer therapeutics since
their discovery in the 1950s. During that time, several clinical trials were initiated
administering adenoviruses into patients with the expectation of tumor cell lysis leading to
improved clinical outcomes (Huebner et al., 1956; Southam, 1960; Webb et al., 1966; Asada,
1974; Webb et al., 1975; Okuno et al., 1978). The results of these studies showed very little
therapeutic benefit; therefore, exploration of adenoviruses for the treatment of cancer came to a
halt. However, since then investigators have expanded upon the knowledge and tools needed to
manipulate the adenoviral genome, and more recent studies have begun using targeted,
conditionally-replicating adenoviruses for the treatment of cancer (Martuza et al., 1991;
Khuri et al., 2000; Reid et al., 2002). Many of these trials involved an adenovirus mutant for
either the E1A or E1B gene products. E1A competitively binds to Rb, resulting in release of the
transcription factor E2F and consequent cell cycle initiation. E1B55K binds to and inactivates
p53, preventing cell cycle arrest and apoptosis. Nearly all tumors possess defects in their p53
and/or Rb pathways. Thus, E1A- or E1B-mutated adenoviruses can still replicate in Rb- or p53defective tumor cells, respectively; however, replication of these mutated viruses is attenuated
in normal cells where these pathways remain intact (Everts and van der Poel, 2005).
In addition to conditional replication, adenoviruses have been genetically modified to
broaden their tropism in order to enhance infectivity in cancer cells that express low levels of
-3-

CAR (Miller et al., 1998; Barnett et al., 2002). The most common involves the addition of a
RGD-4C (CDCRGDCFC) peptide inserted into the HI loop of adenoviral fiber, which allows
the virus to infect cells by binding integrins with a higher affinity (Krasnykh et al., 1998; Fueyo
et al., 2003). Once adenoviruses have been engineered to selectively infect and replicate within
cancer cells, they can further be altered to express therapeutic genes such as tumor suppressors
p53 or PTEN (Köck et al., 1996; Li et al., 2013), or express tumor-associated antigens for
potential anti-tumor immune activation (Cho et al., 2003; Zeng et al., 2011).

Malignant gliomas
Gliomas account for 80% of all malignant, primary brain and CNS tumors, making
them the most common and invasive form of brain tumor in adults. Therapeutic options are still
very limited with first-line treatment combining surgery, radiotherapy and adjuvant
chemotherapy (temozolomide). Regardless of treatment, this disease is invariably fatal with a
median survival that remains at only 12-15 months after initial diagnosis (Central Brain Tumor
Registry of the US, 2004-7). Gliomas are refractory to current surgical and radiotherapeutic
treatments, and the blood-brain barrier provides a considerable obstacle for systemic
chemotherapy. Consequently, conditionally-replicating, oncolytic viruses are being examined
as a more effective mode for targeted treatment of patients with malignant gliomas (Sonabend
et al, 2006; Jiang et al., 2009).

Delta-24-RGD from bench to bedside
Our laboratory is focused on the development and optimization of adenoviruses that can
be employed as therapy for malignant gliomas. Delta-24-RGD (∆24RGD) is a tropismenhanced, oncolytic adenovirus that is under clinical investigation for the treatment of recurring
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gliomas (Fueyo et al, 2000; Fueyo et al, 2003; ongoing clinical trial). This adenovirus is a
genetically altered form of the parental adenovirus type 5 that incorporates the following two
modifications: 1) a 24-base pair deletion in the E1A gene sequence which allows the adenovirus
to replicate selectively and efficiently in tumor cells that have an inactivated Rb pathway
(Fueyo et al., 2000); and 2) a RGD-4C peptide insertion which causes the adenovirus to have a
higher affinity to integrins for their internalization (Fueyo et al., 2003; Jiang et al., 2007). The
Cancer Genome Atlas Project has unequivocally demonstrated that the Rb pathway is abnormal
in at least 75% of malignant gliomas (The Cancer Genome Atlas Research Network, 2008). In
addition, glioma cells express high levels of integrins (Gladson and Cheresh, 1991; Miller et
al., 1998); thus, ∆24RGD is a highly selective, highly potent oncolytic virus for the treatment
of this devastating disease. Currently, ∆24RGD is being tested in a Phase I clinical trial in
patients with recurring gliomas at The University of Texas - M. D. Anderson Cancer Center.
Importantly, previous research in our laboratory demonstrates that glioma cells and brain tumor
stem cells infected with ∆24RGD undergo autophagy that is required for tumor cell lysis (Jiang
et al, 2007; Jiang et al, 2011). There is accumulating evidence that adenovirus infection results
in the induction of dramatic autophagy in the host cells (Ito et al, 2006; Baird et al, 2008; Piya
et al, 2011); however, there is a paucity of information regarding the main regulatory pathways
controlling autophagy in adenovirus-infected cells.

Adenoviruses and autophagy
Autophagy is a tightly regulated program for the degradation of long-lived proteins,
cytoplasmic organelles, and intracellular pathogens to maintain cellular homeostasis (Klionsky
et al., 2000). Autophagy occurs in response to nutrient deprivation and other types of cellular
stress and damage (Kroemer et al., 2010). It is a mechanism of both cell survival and cell death;
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although how these processes are differentiated at the molecular level is not yet characterized
(Codogno and Meijer, 2005). Evidence indicates that host cells undergo autophagy during
adenovirus infection (Ito et al., 2006; Jiang et al., 2007; Jiang et al., 2011; Piya et al., 2011).
Viruses have been known to utilize autophagy to prolong host cell survival for the production
of viral particles, followed by autophagic cell death for their release (Taylor and Kirkegaard,
2008; Lee et al, 2008; Ait-Goughoulte, 2008; Zhou et al, 2009). The signal transduction and
molecular interactions involved in the induction and maintenance of adenovirus-mediated
autophagy remain elusive. We have previously reported that adenoviral protein E1B19K can
interact with beclin 1, a key effector of autophagy (Piya et al., 2011). Although our results
indicate a role for E1B19K in the maintenance of adenovirus-mediated autophagy, the
genetically-modified virus lacking E1B19K was able to induce moderate autophagy. Therefore
further investigation into the mechanism of autophagy after adenovirus infection is required.

Signaling pathways in autophagy
The accepted paradigm of autophagy regulation is represented by a series of molecular
and cellular processes described in starving cells (Noda and Ohsumi 1998; Inoki et al, 2002;
Inoki et al, 2003). A decrease in intracellular ATP due to starvation or stress conditions results
in phosphorylation of adenosine monophosphate-activated protein kinases (AMPK) (Hardie,
2004). AMPKs phosphorylate tuberous sclerosis protein 2 (TSC2), which inactivates
mammalian target of rapamycin (mTOR) (Inoki et al., 2003; Kim et al., 2011). Mammalian
TOR is a pivotal negative regulator of autophagy (Noda and Ohsumi, 1998). In contrast, AKT
phosphorylates mTOR in response to growth factor and nutrient stimulation resulting in
inhibition of autophagy (Inoki et al., 2002). Thus, the AKT signaling directs the cell to halt
recycling of cellular components via autophagy, and initiates transcription and cell proliferation

-6-

Figure 2. The archetypal signaling pathway regulating the induction of autophagy. AMPK
are activated by numerous stimuli, including starvation. AMPKs phosphorylate TSC2 which
inhibits mTOR, thus allowing autophagy to proceed. AKT is also phosphorylated by numerous
stimuli, including growth factors. AKT inhibits TSC2 phosphorylation; thus, AKT positively
regulates mTOR phosphorylation and autophagy inhibition. P70S6K is a substrate of mTOR
that leads to transcription.
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through activation of mTOR and the downstream substrate p70S6K (Jefferies et al., 1997;
Inoki et al., 2002). AMPK and AKT function inversely to activate or inhibit autophagy,
respectively, through TSC2. As such, AKT inactivates TSC2, permitting mTOR to inhibit
autophagy (Inoki et al., 2002). (Figure 2)
These initial interactions induce or inhibit autophagy by influencing downstream
effectors such as beclin 1 and microtubule-associated protein 1A/1B-light chain 3 (LC3).
Beclin 1 is part of a complex that initiates nucleation of the isolation membrane from the ER
(Figure 3) (Kihara et al., 2001). LC3-I protein is lipidated and cleaved to form LC3-II, and
LC3-II is inserted into the autophagosomal membrane to assist in elongation (Mizushima et al.,
2001). Simultaneously, p62 recruits ubiquitinated protein aggregates, damaged organelles, and
intracellular pathogens to be engulfed by the autophagosomal membrane (Pankiv et al., 2007;
Levine et al., 2011). The contents are degraded upon fusion of autophagosomes with
lysosomes, and metabolic precursors are recycled by the cell (Figure 3).

Importantly,

autophagy can be detected experimentally by these molecular and morphological phenomena:
1) lipidation and cleavage of LC3-I to LC3-II; 2) selective degradation of the p62; and 3)
visualization of double membrane-bound autophagic vacuoles by electron microscopy
(Mizushima et al., 2010).
Beclin 1 was originally isolated and identified as a B cell lymphoma/leukemia-2 (Bcl-2)
interacting protein (Liang et al., 1999). Bcl-2 binds to beclin 1, blocking the interaction of
beclin 1 with phosphatidylinositol 3 kinase class 3 (Pi3KC3) thereby preventing initiation of
autophagy (Itakura et al., 2008). Importantly, recent studies on starvation-induced autophagy
demonstrated that the mitogen–activated protein (MAP) kinase c-Jun N-terminal kinase 1
(JNK1) phosphorylates Bcl-2 and inhibits its ability to interact with beclin 1, thereby
facilitating autophagy (Wei et al, 2008). The nature of JNK-mediated phosphorylation of Bcl-2
remains under investigation and has not been addressed in adenovirus-induced autophagy.
-8-

Figure 3. The molecular events characteristic of autophagy. The beclin 1 complex initiates
nucleation of the isolation membrane. LC3-I is cleaved and lipidated forming LC3-II, which is
inserted into the membrane for assistance in elongation. P62 recruits aggregated proteins,
damaged organelles, and foreign pathogens to the autophagosome. Autophagosomes fuse with
lysosomes, where digestive enzymes degrade the contents into their basic components:
peptides, lipids, carbohydrates.
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C-Jun N-terminal kinase
C-Jun N-terminal kinase (JNK) is a mitogen-activated protein kinase that is involved in
numerous signal transducing networks leading to a range of cellular endpoints including cell
proliferation, apoptosis and, most recently discovered, autophagy (Johnson and Lapadat, 2002;
Wei et al, 2008). There are three isoforms of JNK (JNK1, JNK2, and JNK3) with increased
variation due to alternative splicing. JNK1 and JNK2 often have redundant roles; however,
JNK3 is expressed mainly in neurons and the heart, and is primarily involved in embryonic
development (Martin et al., 1996; Gupta et al., 1996; Kuan et al., 1999).
There is evidence regarding JNK activation during adenovirus infection. One team of
investigators reported JNK was activated upon adenoviral fiber binding to the coxsackie
adenovirus receptor on the cell surface during infection of respiratory cells (Tamanini et al.,
2003; Tamanini et al., 2006). Most of the investigations regarding adenovirus-induced JNK
activation involve the antiviral cellular immune response. JNK has long been recognized as an
important immune modulator in response to pathogens, including adenovirus. Recognition of
adenoviral oligonucleotides by cellular receptors and proteins (e.g., Toll-like receptor 9 and
retinoic acid-inducible gene 1) stimulates JNK signaling for expression of pro-inflammatory
cytokines (Ichijo H., 1999; Johnson and Lapadat, 2002; Barton and Medzhitov, 2003;
Minamitani et al., 2011). Furthermore, adenovirus-infected cells express and release type 1
interferons at high levels via JNK-dependent and independent pathways (Basner-Tschakarjan
et al, 2006; Minamitani et al., 2011). Interferons, the gold standard for an anti-adenoviral
immune response, are also potent activators of JNK signal transduction leading to apoptosis
(Ichijo et al., 1997; Caraglia et al., 1999; Sung et al, 2001; Takada et al., 2005); nevertheless,
adenoviruses have numerous mechanisms for blocking apoptosis downstream of JNK (Rao et
al., 1992; White, 1993). Additionally, type 1 interferons lead to the up-regulation of 2′,5′oligoadenylate synthetase (OAS) (Rutherford et al., 1988). OAS recognizes adenoviral double
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stranded RNAs and produces 2'-5' linked oligoadenylates, which trigger activation of RNase L
and consequent JNK activation (Hovanessian et al., 1977, Zhou et al., 1993; Siddiqui et al.,
2012). The canonical pro-inflammatory response to adenovirus also includes tumor necrosis
factor-alpha (Sung et al., 2001). Tumor necrosis factor-alpha (TNFα) regulates apoptosis
signal-regulating kinase 1 (Ask1)-dependent JNK phosphorylation via the TNF receptorassociated factor (TRAF) 2 or 6 adapter proteins (Nishitoh et al., 1998; Yoon et al., 2008).
Therefore, JNK phosphorylation in adenovirus-infected cells may result from a multitude of
molecular events, triggered by both cellular and viral elements in the battle to control
production and dissemination of the virus.
JNK is also known to play a role in autophagy. Recent studies on starvation-induced
autophagy demonstrated that one isoform of the JNK family, JNK1, activates autophagy
through regulation of Bcl-2/beclin 1 interactions (Wei et al., 2008). In addition, JNKs may play
a role in the regulation of ER stress-induced autophagy and oxidative stress-induced autophagy
(Ogata et al., 2006; Wong et al., 2010), as well as in etoposide- and staurosporine-induced
autophagic cell death (Shimizu et al., 2010). Moreover, the activation of JNK-dependent
autophagy by cancer chemotherapeutic agents is currently being investigated. Resveratrol
requires JNK to induce autophagic cell death in chronic myelogenous leukemia (Puissant et al.,
2010). The investigational compounds oridonin and bufalin also activate autophagy in cancer
cells through JNK-dependent mechanisms (Cui et al., 2007; Xei et al., 2011). JNK has also
even been implicated in regulating autophagy activated by insulin-like growth factor-1 and
tumor necrosis factor-alpha signaling (Jia et al., 2006). The link between JNK and autophagy
is convincing; however, the molecular events involved upstream and downstream of JNK
activation are unclear and vary among different forms of stress and stimuli. Moreover, the role
of JNK in adenovirus-induced autophagy has not been investigated.
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Autophagy and antigen presentation
Autophagy is also a well-documented mechanism of immune presentation of self and
foreign antigens (Münz et al., 2000; Paludan et al., 2005; Zhou et al., 2005; Dengjel et al.,
2005; Schmid et al., 2007; Li et al., 2008). It is an important part of the innate immune system;
protecting cells and organisms against invasive pathogens (Levine et al., 2011). In addition to
the direct sequestration and degradation of these pathogens, autophagy participates in the
processing of antigens for presentation in major histocompatibility (MHC) molecules on the
surface of virus-infected cells (Paludan et al., 2005; Crotzerand Blum, 2009; English et al.,
2009). It is also hypothesized that extracellular autophagosomes filled with foreign antigens
will be released from the infected cell, via lytic or non-lytic processes, and may be phagocyted
by dendritic cells leading to professional presentation of foreign antigens (Schmid et al., 2007).
Autophagy has been implicated in the processing of viral antigens primarily for
presentation on MHC class II molecules (Jaraquemada et al., 1990; Münz et al., 2000;
Paludan et al., 2005). During infection with Epstein-Barr virus, the nuclear antigen 1 (EBNA1)
is processed during autophagy, and presented on MHC class II molecules at the cell surface for
activation of CD4+ T cells (Münz et al., 2000; Paludan et al., 2005). The same was observed
after infection with a recombinant vaccinia virus (Jaraquemada et al., 1990). However, the role
of autophagy in processing adenoviral antigens is currently unknown. (Figure 4)

Immunotherapy in cancer
Anti-tumor immune activation is thought to be able to eradicate cancer
completely. This innovative therapeutic strategy involves reprogramming the immune system
to attack and kill tumor cells (Waldmann, 2003). Investigators hypothesize this initial attack
will be followed by immune memory, reducing the possibility of recurrence and secondary
tumor formation (Klebanoff et al., 2006). Immunotherapy for cancer comes in many forms.
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MHC class II
Lysosome
MIIC

Autophagosome

Autophagolysosome

Figure 4. The role of autophagy in self and foreign antigen presentation. Protein
aggregates, damaged organelles and intracellular pathogens are recruited to and engulfed by
autophagosomal membranes. Autophagosomes fuse with lysosomes for degradation of the
content by digestive enzymes. The autophagolysosomes fuse with MHC class II compartments
(MIIC) and peptides are loaded onto MHC class II molecules for presentation to immune cells
at the surface of the cell.
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Adoptive immune cell therapy involves the reprogramming of a patient’s immune cells to
target cancer cells in vitro, followed by implantation in combination with adjuvant cytokines
for an anti-tumor immune response (Dudley et al., 2002; Phan et al., 2003). Enhanced
activation of the immune system through the administration of cytokines (e.g. interleukin 2) has
been examined as a therapeutic option alone, and in combination with each form of
immunotherapy (Atkins et al., 1999). Another immunotherapeutic approach involves antibodies
that bind to and inactivate T cell inhibitory receptors, such as cytotoxic T-lymphocyteassociated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) (Schwartz, 1992;
Pardoll, 2012). These receptors inhibit T cell function, and are often deregulated by cancer
cells in an attempt to evade the immune system. Thus, antibodies and peptides have been
designed to block this mechanism, and are currently under clinical investigation for the
treatment of various cancers (Phan et al., 2003; Brahmer et al., 2010). Most importantly,
recombinant viruses have been investigated as anti-tumor vaccines due to the ease with which
they can be modified to carry immune-related genes or tumor-associated antigens (Rosenberg
et al., 1998; Bendandi et al., 1999; Gulley et al., 2002).

Tumor-associated antigens in gliomas
A tumor-associated antigen is an immunogenic peptide that is expressed selectively by
cancer cells. Many immunotherapeutic approaches encompass tumor-associated antigens that
are presented to the immune system in order to activate an anti-tumor immune response (Chen
et al., 1996 Rosenberg et al., 1998; Perricone et al., 2000; Cho et al., 2003; Sorensen et al.,
2009; Zeng et al., 2011). Epidermal growth factor receptor (EGFR) is frequently up-regulated
in cancer, particularly malignant gliomas. Moreover, the EGFR variant III (EGFRvIII) is an
extremely prevalent, tumor-specific mutation (Moscatello et al., 1995) that is commonly
expressed in brain tumors and brain tumor stem cells (Shinojima et al, 2003). It is also a highly
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immunogenic protein; thus, this tumor-associated antigen has become the focus of many
immunotherapeutic strategies for the treatment of malignant gliomas (Sampson et al., 2009).

Anti-cancer vaccines
Immune modulation using conditionally replicating, oncolytic adenoviruses is being
examined as a more effective vehicle for the targeted treatment of cancer (Bridle et al, 2010;
Melcher et al, 2011; Pantuck et al; 2004). The safety and immunogenicity of adenoviruses
make them attractive for the development of vaccine platforms (Tatsis et al., 2004; Matthews,
2011). Adenoviruses activate the innate immune system through the expression of pathogenassociated molecular patterns and subsequent induction of the secretion of inflammatory
cytokines. Infection is rapidly followed by the release of interleukin-6, interleukin-12, and
tumor necrosis factor-α and accumulation of macrophages and dendritic cells in lymphatic
tissues (Medzhitov and Janeway, 2000; Zhang et al., 2001; Schnell et al., 2001). The humoral
immune-response includes the development of virus-neutralizing antibodies directed against
the surface loops of the viral hexon (Wohlfart, 1988), and the penton base or the fiber (Hong et
al., 2003). Therefore, infection by a recombinant adenovirus can prime the environment for an
immune response against an ectopic transgene or a cancer-specific epitope inserted within the
genome of the virus; thus, taking advantage of the cross-priming process (Carbone and Heath,
2010). For these reasons, adenoviruses are being extensively examined as immunotherapeutic
vectors for a broad variety of diseases including HIV and cancer (Matthews, 2011).
The adenoviral genome is large and easily manipulated; thus, many investigators are
developing recombinant adenoviruses expressing tumor-associated antigens in order to prime
the environment for an immune response against tumor cells (Chen et al., 1996; Rosenberg et
al., 1998; Perricone et al., 2000; Sorensen et al., 2009). The first FDA-approved therapeutic
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cancer vaccine, Provenge (Sipuleucel-T) activates patient’s immune cells by professional
antigen presentation of prostatic acid phosphatase (PAP), which is selectively over-expressed in
most prostate cancer cells. Immunotherapy using viral vectors has already shown promising
results for tumor suppression in certain cancers (Mellman et al, 2011; Huber et al, 2012).
Cancer immunotherapy using oncolytic adenoviruses is an innovative means of recruiting a
patient’s immune system to eliminate cancer. It can easily be adapted to personalized medicine,
using the antigen expression profile of each particular patient’s tumor to determine which
combination of recombinant adenoviruses would be best for treatment.

Hypothesis and aims
Accumulating evidence has indicated that adenoviruses induce autophagy that is required
for host cell lysis, but the regulation of autophagy in adenoviral infected cells remains under
investigation. We undertook this study to examine the signal transduction involved in the
regulation of adenovirus-induced autophagy. In addition, autophagy promotes antigen
processing and presentation at the cell surface for consequent immune cell activation. We
intend to investigate the molecular mechanisms underlying the initiation and maintenance of
autophagy in adenovirus-infected cells which will offer new avenues in the precise regulation
of viral antigen presentation. Understanding the mechanisms of action by which adenoviruses
activate cell lysis as well as how the host cell facilitates an antiviral immune response will pave
the way for novel anti-cancer vaccines that can leverage the autophagy pathways. My central
hypothesis is that adenovirus-infected cells demonstrate an activation of autophagy regulatory
pathways that can be identified and characterized. One prediction of this hypothesis is that
these signaling pathways will be required for virus-derived antigen presentation through
autophagy. To test our hypothesis, we will investigate the components of the canonical
pathway regulating starvation-induced autophagy, including AMP kinases, TSC2, AKT,
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mTOR, and p70S6K. We will use wild type and recombinant human adenoviruses to infect
human normal and cancer cell lines in order to determine the extent to which these kinases are
active and the role they have to play in adenovirus-induced autophagy. In addition, we will
examine the activation of the MAP kinase JNK signaling cascade in response to adenovirus
infection in vitro and in vivo. We will determine the role of JNK activation in the regulation of
Bcl-2/beclin 1 heterodimers, as well as discover the extent to which this pathway is required for
adenovirus-mediated autophagy. We will establish a mechanistic continuum linking adenovirus
infection, JNK-mediated autophagy, and adenovirus-derived antigen presentation. Lastly, we
will develop targeted, recombinant adenoviruses expressing the EGFRvIII tumor-associated
antigen that are presented at the host cell surface via autophagy. These novel viruses will have
the potential to leverage their innate capacity to induce autophagy and antigen presentation, in
order to mount an immune response against EGFRvIII-expressing malignant glioma cells. This
unique therapeutic strategy aims to improve the currently fatal prognosis of patients suffering
from malignant gliomas.

- 17 -

Chapter II: Materials and Methods

Cell culture. MRC5 immortalized, healthy lung fibroblasts, U251 malignant glioma, HeLa
cervical carcinoma, A549 lung carcinoma, HEK293 immortalized human embryonic kidney
and U87

malignant glioma cell lines were obtained from the American Type Culture

Collection. HeLa and HEK293 cells were cultured in Dulbecco's Modified Eagle Medium
(DMEM) 1X, whereas MRC5, U251, and A549 cells were cultured in DMEM/F-12 50:50
medium (Gibco, Invitrogen), each with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin, and incubated at 37°C in 5% CO2 in air. U87 MG cells were cultured
in Minimum Essential Medium Eagle (MEM) with 10% FBS, 1% penicillin/streptomycin, and
1% essential amino acids under the same conditions. The JNK wild-type and knock-out mouse
embryonic fibroblasts (MEF) (JNK wt, JNK1-/-, JNK2-/-, JNK1/2-/-) were provided by Dr.
Zhimin Lu (M.D. Anderson Cancer Center, Houston, TX). The AMPKα1 wild-type and knockout MEF cells were obtained from Keith Laderoute (SRI International, San Francisco, CA).
MEF cells were cultured in DMEM/F-12 50:50 medium with 10% FBS at 37°C in 5% CO2 in
air.

Reagents. The JNK kinase inhibitor SP600125, anisomycin, paclitaxol and bafilomycin A1
were purchased from Sigma-Aldrich. Rapamycin was purchased from Calbiochem.
Recombinant human protein interferon-γ (IFNγ) was purchased from Prospec (East Brunswick,
NJ). Antibodies to phospho-AKT (S473), AKT, AMPKα1, TSC2, LC3, phospho-JNK
(T183/Y185, T221/Y223), phospho-c-Jun (S63), c-Jun, beclin 1 were purchased from Cell
Signaling Technologies. Anti-phospho-Bcl-2 and anti-JNK2 were purchased from Abcam.
Anti-JNK1, anti-JNK3, anti-panJNK, anti-E1A, anti-p62, anti-actin, and anti-Bcl-2 antibodies
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were purchased from Santa Cruz Biotechnology. Anti-adenoviral hexon was purchased from
Novus Biologicals, and anti-adenoviral fiber from ThermoScientific. Allophycocyanin (APC)conjugated anti-mouse secondary antibodies and fluorescein isothiocyanate (FITC)-conjugated
secondary antibody were purchased from Santa Cruz Biotechnology.

Adenoviral production and infection. The Delta-24-RGD (∆24RGD) and wild-type adenovirus
were produced previously by our laboratory in collaboration with Roman Alemany (Barcelona,
Spain) (Fueyo et al., 2000; Fueyo et al., 2003). Briefly, the ∆24RGD adenovirus was
constructed from a modified adenovirus type 5 genome (Microbix Biosystem Inc., Ontario,
Canada) as follows. The backbone plasmid pXCl encompasses the adenovirus type 5 genome
from nucleotides 22-5790. Using phosphorylated mutagenic primers, 24 bases from 919-943
were looped out and deleted, corresponding to amino acid residues L, T, C, H, E, A, C, and F
of the E1A protein sequence. The E1 fragment containing the 24-bp deletion was isolated from
the plasmid pXC1-∆24 and cloned by homologous recombination into the ClaI–digested
plasmid pVK503 containing the RGD-4C sequence inserted into the HI loop of adenoviral fiber
(Pasqualini et al., 1997). The full genome of the new virus was released from the plasmid
backbone by digestion with PacI, and the linear viral DNA was transfected into HEK 293 cells
to rescue the ∆24RGD adenovirus. The Delta-24-FvIII (∆24FvIII) was constructed through
inserting the EGFRvIII epitope (LEEKKGNYVVT) into the HI loop of fiber protein between
amino acid 533 and 534 (Krause et al., 2006). First the sequence coding for the EGFRvIII
epitope was incorporated into the fiber gene in vector pXK-F containing XbaI–KpnI fragment
of pVK500C (Mahasreshti et al., 2006) through site-directed mutagenesis. Next, the Xba I-Kpn
I fragment from the resulting vector pXK-FvIII was co-tranduced with SwaI-linearized
pVK500C.delta-24 into E. coli BJ5183 to allow for homologuos recombination (Piao et al.,
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2009). The plasmids were transfected into HEK293 cells in order to rescue the virus which
was then propagated in A549 cells. Cells were seeded 24h prior to adenoviral infection. They
were infected with adenoviruses at cell line-specific multiplicities of infection (MOI) for
specified time-points. Floating and attached cells were collected for respective experiments as
described below.

Human Phospho-kinase Antibody Array kit. The Human Phospho-kinase Antibody Array Kit
was purchased from RandD systems. The array was performed according to the manufacturer’s
protocol. Briefly, MRC5 human lung fibroblasts were infected with wild-type adenovirus for
16, 32, and 48 h. Uninfected cells (0h) were used as a control. The cells were collected and
lysed using Lysis Buffer 6 from the kit, and the concentration of protein determined by the
Bradford Protein Assay (Bio-Rad). After blocking the nitrocellulose membranes bound with
phospho-specific antibodies to each kinase in duplicate, they were incubated with 400 µg of
protein overnight at 4oC. The membranes were washed and incubated with Detection Antibody
Cocktails of biotinylated antibodies specific for the phosphorylated kinases. HRP-conjugated
Streptavidin antibodies and chemiluminescent detection reagents were used to visualize the
amount of protein.

SDS-PAGE and western blot analysis. Cells were lysed with RIPA lysis buffer [150 mM
NaCl, 50 mM Tris-HCl pH 7.5, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium
deoxycholate, 1% NP-40, protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktail
(Millipore)]. Protein concentrations were determined using a Bradford Protein Assay (BioRad). Protein samples (25 µg) in 1X SDS loading buffer were boiled and loaded into trisglycine SDS-PAGE gels (Invitrogen). Samples were separated via electrophoresis at a constant
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voltage of 100v (~2 1/2 hr) in 1X Tris-glycine running buffer. Gels were then transferred to
polyvinylidine fluoride membrane via western blotting (25v for 40 min in a Bio-Rad semi-dry
transfer apparatus). The membranes were blocked using 5% non-fat milk in 1X TBS-T (0.05%
Tween) for 1 h at room temperature and then incubated overnight at 4°C in a primary antibody
at appropriate dilutions as follows: phospho-AKT (S473; 1:1000), AKT (1:1000), AMPKα1
(1:1000), TSC2 (1:500), LC3 (1:1000), phospho-JNK (T183/Y185, T221/Y223; 1:1000),
phospho-c-Jun (S63; 1:1000), c-Jun (1:1000), beclin 1 (1:500), ahospho-Bcl-2 (S87; 1:1000),
JNK1 (1:5000), JNK2 (1:1000), JNK3 (1:500), panJNK (1:1000), E1A (1:5000), p62 (1:1000),
actin (1:5000), and Bcl-2 (1:500). Membranes were washed three times with TBS-T (0.05%
Tween) and then incubated at room temperature for 1 h with appropriate secondary antibodies
(ThermoScientific; 1:4000) prepared in 1% non-fat milk in TBS-T. SuperSignal West Femto
(ThermoScientific) and HyBlot CL autoradiography film (Denville Scientific Inc.) were used to
visualize protein bands.

DNA vectors and transfection. The pEGFP-LC3 plasmid used to detect GFP-LC3 puncta was
purchased from Addgene. The plasmid was amplified in DH5α MAX Efficiency competent
cells (Invitrogen). Individual clones were selected in Luria broth and 100 µg/ml kanamycin
(Sigma-Aldrich). The vector was isolated and purified (Miniprep, Qiagen) from each colony.
U87 MG cells were seeded 24 h prior to transfection to about 60-70% confluency. XtremeGENE HP DNA transfection reagent (Roche) was used to transfect vectors into cells. In
200 µl of serum-free media, 2 µg of plasmid was combined with 10 µl of transfection reagent
and allowed to incubate at room temperature for 20 min. The mixture was added drop-wise to 1
ml of culture media in a 6-well plate and incubated with the cells for 48 h prior to treatment.
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RNA interference. For short-hairpin RNA transfection of TSC2, the shTSC2 plasmid was
purchased from OriGene. FuGENE 6 DNA transfection reagent (Roche) was used to introduce
the plasmid into U251 cells. In 200 µl of serum free media, 2 µg of shRNA plasmid was
incubated with 6 µl of transfection reagent at room temperature for 15 min. The mixture was
added to cells for 48 h. A stable cell line was established through puromycin selection (0.5
µg/ml). U87 MG cells were seeded into 6-well plates 24 h prior to small-interfering RNA
(siRNA) transfection. INTERFERin (Polyplus Transfection, Illkirch, France) was employed to
transfect the siRNAs against JNK1 and JNK2 into cells according to the manufacturer’s
protocol. Briefly, 50nM siRNA oligonucleotides were combined with 10µl of transfection
reagent in 200 µl serum free media and added to cells after 15 min of incubation at room
temperature. SiRNA oligonucleotides for JNK1 (M-003514-04-0005) and JNK2 (M-00350502-0005) were purchased from Dharmacon (ThermoScientific).

Co-immunoprecipitation. Cells were infected with AdWT or ∆24RGD for up to 48 h. Floating
and attached cells were collected and lysed with immunoprecipitation (IP) lysis buffer (100
mM NaCl, 50 mM Tris-HCl pH 7.4, 2 mM EDTA, 10% glycerol, 1% IgePal CA-630). The cell
samples were pre-cleared with Protein A/G (1:1) agarose beads for 2 h. An anti-Bcl-2 antibody
(1:100) or anti-p62 antibody (1:100) was added to lysates to rotate at 4oC overnight. Complexes
of proteins were immobilized with Protein A/G (1:1) agarose beads. Immunoprecipitated
samples, pre-cleared beads, and 5% input were analyzed via western blotting. Antibodies to
beclin 1 (1:1000), adenoviral hexon (1:10,000), and adenoviral fiber (1:1000) were used to
detect their interaction with Bcl-2 or p62. Clean-Blot IP Detection Reagent HRP
(ThermoScientific) was used to visualize proteins bound by all anti-rabbit primary IgGs,
reducing the detection of heavy and light chains.
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Animal protocol. All animal studies were performed in the Department of Veterinary Medicine
at The University of Texas MD Anderson Cancer Center in accordance with institutional
guidelines and ethical guidelines for experimental animal care and approved by the MD
Anderson IACUC. U87 human glioma cells (5 x 105) were engrafted into the caudate nuclei of
athymic mice using a guide-crew system. In brief, a 2.6-mm guide screw with a 0.5-mm
diameter central hole is implanted into a drill hole made 2.5 mm lateral and 1 mm anterior to
the bregma. It is capped with a stylet between treatments. Tumor cells or therapeutic agents are
injected using the 26-gauge needle of a Hamilton syringe with a cuff to determine the depth of
injection. The procedure has been described and validated previously (Lal et al., 2000). Three
days after cell implantation, the animals were given 5 µl intratumoral injections of ∆24RGD
(106 pfu/ml) or PBS. Animals exhibiting generalized or local signs of disease were euthanized
using a CO2 chamber (~28-35 days after cell implantation). Their brains were then removed,
fixed in 4% formalin for 48 h, and embedded in paraffin, and 5µm slices of them were mounted
on slides.

Tissue immunofluorescence
Slides were baked for 45 minutes at 60°C followed by deparaffinization in xylene and
rehydration in serial dilutions of ethanol employing the following procedure: 2X5 min in 100%
ethanol; 2X5 min in 95% ethanol; 5 min in 70% ethanol; 3X5 min in PBS + 0.05% Tween-20.
Hematoxylin- and eosin-stained coronal sections were evaluated for evidence of tumors. Heatmediated antigen retrieval was performed on the tissue using 10 mM citrate buffered to pH 6.0
and a pressure cooker for 20 min followed by 20 min at room temperature to cool. The tissues
were blocked using appropriate serum and a streptavidin/biotin blocking kit (Vector Labs).
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Anti-phospho-JNK (T183/Y185, T221/Y223; Cell Signaling; 1:100) or anti-phospho-Bcl2
(S87; Abcam; 1:100) and anti-hexon (ThermoScientific; 1:500) primary antibodies were
applied overnight at 4°C followed by incubation with their respective biotin-conjugated
secondary antibodies (Vector Labs; 1:100). Dylight 594- or Dylight 488-conjugated
streptavidin (Vector Labs; 1:100) were used to visualize the co-localization of infected cells
(i.e., hexon) and p-JNK or p-Bcl-2. Vectashield Mounting Media with DAPI (Vector Labs) was
used to stain nuclei and seal slides. Images were captured on a Zeiss Axiovert Zoom
fluorescence microscope (Carl Zeiss, Inc.) equipped with AxioCam MRM camera and 40x 1.3
oil EC Plam-NEOFLUAR objective, using Immersol (n = 1.518) at room temperature. The
acquisition software utilized was AxioVision Release 4.7.1 (Carl Zeiss, Inc).

Electron microscopy. Cells (>1,000,000) were fixed in a solution that comprised 3%
glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3). The samples
were treated with 0.1% cacodylate-buffered tannic acid and then fixed for an additional 1 hour
with 1% buffered osmium tetroxide. They were then stained with 1% uranyl acetate. All
reagents were obtained from Sigma-Aldrich. The samples were dehydrated in ethanol at
increasing concentrations, infiltrated, and then embedded in Spurr's low-viscosity medium.
They were polymerized for 2 days at 70°C. Ultrathin sections were cut in a Leica
Ultracutmicrotome, stained with uranyl acetate and lead citrate in a Leica EM stainer, and
visualized using a JEM-1010 transmission electron microscope (JEOL USA Inc.) at an
accelerating voltage of 80 kV. Digital images were obtained using an imaging system from
Advanced Microscopy Techniques.
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Flow cytometry. Cells were treated for respective time-points, trypsinized and collected in PBS
with 1% BSA. Interferon gamma (INFγ) was added to cells at 300 units/mL. Bafilomycin A1
was used at indicated concentrations. Live cells were stained for adenoviral antigens using a
combination of mouse anti-adenovirus (blend) coating (Millipore; 1:75) and mouse antiadenovirus fiber antibodies (1:75) for 30 min at 4°C. After washing, the cells were stained with
allophycocyanin (APC)-conjugated anti-mouse secondary antibodies (1.75) for 30 min at 4°C.
For detection of the EGFRvIII epitope (LEEKKGNYVVT), a monoclonal antibody termed
L8A4 (1:25) was graciously provided by Dr. Amy Heimberger (MD Anderson Cancer Center,
Houston, TX). After 30 min incubation at 4oC, the cells were stained with a fluorescein
isothiocyanate (FITC)-conjugated secondary antibody. The live cells were analyzed using a BD
FACSCalibur (Becton-Dickenson). Dead cells were excluded using propidium iodide or
ethidium homodimer-1 staining prior to analysis. The data represent at least four independent
experiments.

Splenocyte isolation and activation. All animal studies were performed in the veterinary
facilities at The University of Texas – M. D. Anderson Cancer Center in accordance with
institutional guidelines and ethical guidelines for experimental animal care and approved by the
MD Anderson IACUC. C57BL/6 mice were infected with 108 plaque forming units of
∆24RGD adenovirus twice (Day 1 and 3) intracranially through the guide-screw method
described above. The animals were euthanized using a CO2 chamber on Day 14 and the spleens
were collected. The spleens were manually homogenized and passed through a 100 µm nylon
cell strainer. The red bloods cells were removed using ACK Lysing Buffer (Lonza). In parallel,
wild-type and JNK1/2 DKO (JNK1/2 -/-) MEF cells were seeded 1 x 105 in a 6-well plate (in
triplicate). The cells were infected with 100 MOI of ∆24RGD for 24 h, trypsinized and re-
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plated into a 96-well plate at 5 x 104 cells per well in RPMI 1640 media with 10% FBS and 5
µM beta-mercaptoethanol. The splenocytes (1 x 106 cells) from naïve and immunized mice
were incubated with the pre-infected MEF cells in culture for 24 h. For experiments including
blocking antibodies, the pre-infected MEF cells were incubated with 2µg of anti-mouse MHC
Class I (H-2Kd; eBioscience), anti-mouse MHC Class II (I-A/I-E; eBioscience), or mouse IgG
antibodies (Santa Cruz) 2 h prior to co-culture with primed splenocytes. The splenocytes were
then incubated with the pre-infected MEF cells and blocking antibodies for 24 h. The Mouse
IFNγ ELISA Kit (ThermoScientific) was used to evaluate the concentration of IFNγ in media
extracted from the co-culture. The ELISA was performed according to the manufacturer’s
instructions. In brief, 50 µl of co-culture media was incubated in a 96-well plate coated with
antibodies to IFNγ. A biotinylated IFNγ detection antibody followed by HRP-conjugated
streptavidin and chemiluminescent reagents revealed the concentration of IFNγ in each sample.
The absorbance (450nm-550nm) was analyzed by an Omega Microplate Reader (BMG
Labtech) and the concentration of IFNγ (pg/ml) was determined by comparing to the standard.

Statistical analysis. The two-tailed Student t-test was used to determine the statistical
significance of treated and infected samples relative to control samples. Only p values less than
0.05 were accepted as statistically significant.
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Chapter III: The archetypal signaling pathway for autophagy is not employed during
adenovirus mediated autophagy.

Rationale and Expectations:
The archetypal signaling events that regulate the induction of autophagy have been
investigated thoroughly (Figure 3). Many forms of cellular stress, including starvation,
stimulate phosphorylation of adenosine monophosphate-activated protein kinases (AMPK)
(reviewed by Hardie, 2004). AMPKs phosphorylate tuberous sclerosis protein 2 (TSC2),
facilitating autophagy through inhibition of a pivotal negative regulator of autophagy, the
mammalian target of rapamycin (mTOR) (Inoki et al., 2003; Kim et al., 2011). Mammalian
TOR is a well-established inhibitor of autophagy (Noda and Ohsumi, 1998). Phosphorylation of
mTOR through AKT signaling results in inhibition of autophagy (Inoki et al., 2002). The AKT
pathway is activated by growth factors and nutrients; thus, signaling to the cell that recycling of
cellular components through autophagy is not necessary, and energy should be directed toward
transcription and cell proliferation through activation of mTOR and the downstream substrate
p70S6K (Jefferies et al., 1997; Inoki et al., 2002). AMPK and AKT function inversely to
activate or inhibit autophagy, respectively, through TSC2. As such, AKT inactivates TSC2,
permitting mTOR to inhibit autophagy (Inoki et al., 2002). Therefore, upon investigating
adenovirus-mediated autophagy, we initially expected to observe similar variations in the
phosphorylation of key components of this canonical signaling pathway.
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Results:

AKT and mTOR, but not AMPK, are phosphorylated in adenovirus-infected cells. Our
investigation began by utilizing a high-throughput antibody array to evaluate the
phosphorylation status of numerous kinases during adenovirus infection. We infected MRC5
immortalized, healthy lung fibroblasts with wild-type adenovirus (AdWT) for increasing timepoints and surveyed the cellular protein content using a Human Phospho-kinase Antibody
Array (RandD Systems). The array revealed a multitude of kinases that exhibited changes in
phosphorylation status in response to adenovirus infection (Figure 5, Table 1). Several key
modulators of the archetypal pathway to autophagy initiation were included in the array.
Unexpectedly, we observed that there was minor changes in the phosphorylation of two AMPK
isoforms (AMPKα1 and AMPKα2), whose activation by phosphorylation elicits autophagy
(Kim et al., 2011). Moreover and in agreement with this data, both AKT and mTOR were
highly phosphorylated after adenovirus infection (Figure 6). We detected a 22-fold increase in
phosphorylated AKT as early as 16h after infection that was maintained up to 48h. The
phosphorylation of mTOR exhibited a time-dependent increase, peaking at a 31-fold phosphoprotein level 48h after infection (Figure 6). We also observed a 35-fold increase in p70S6K,
which is a confirmed substrate of mTOR (Jefferies et al., 1997). In addition, we validated the
phosphorylation of AKT in U87 malignant glioma (U87 MG) cells infected with the tropismenhanced ∆24RGD adenovirus. Infected cells exhibited an 11-fold increase in phospho-AKT
levels that corresponded in time with LC3-I to LC3-II conversion, the marker of autophagy
(Figure 7). Our data reveals the highest levels of AKT and mTOR phosphorylation were
observed at 48 h (Figure 6-7); the last time-point examined and a time-point when autophagy is
active (Figure 7).
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Figure 5. A high-throughput profile reveals numerous phosphorylated kinases during
adenovirus infection. The Human Phospho-kinase Antibody Array (R&D Systems) was
employed to examine the phosphorylation status of a variety of kinases during infection of
immortalized MCR5 healthy lung fibroblasts with wild-type adenovirus (AdWT). Cells were
infected at an MOI of 50 for the indicated time-points and whole-cell protein lysates were
analyzed by the array. The spots indicate phospho-protein levels and controls in duplicate.
Please see table 1 for list of kinases.
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Table 1. A list of kinases detected by the Human Phospho-kinase Antibody Array and
their corresponding phosphorylation site(s). The table includes the phosphorylation site(s)
that was detected by the array as well as the coordinates where the kinase can be found within
the array. Kinases highlighted in orange are components of the canonical AMPK/Akt/mTOR
pathway of autophagy, while kinases highlighted in blue are of the MAP kinase signaling
cascade.
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Figure 6. The phosphorylation status of proteins during adenovirus infection contradicts
the archetypal autophagy pathway. A, The expression levels of phosphorylated protein for
AMPKα1 (T174), AMPKα2 (T172), Akt (S473), mTOR (S2448), and p70S6K (T421/S424)
were evaluated in immortalized MCR5 healthy lung fibroblasts during adenovirus infection.
Cells were infected with wild-type adenovirus (AdWT) at an MOI of 50 for the indicated timepoints, and whole-cell protein lysates were analyzed using the Human Phospho-kinase
Antibody Array. The spots indicate phospho-protein levels in duplicate. B, Densitometry was
performed on each spot and then graphed as an average of the two. Fold-change in phosphoprotein levels were generated relative to uninfected cells (0h).
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Figure 7. ∆24RGD infection stimulates AKT phosphorylation in malignant glioma cells
undergoing autophagy. U87 MG cells were infected with UV-inactivated and active ∆24RGD
adenovirus at an MOI of 50 for indicated time-points. AKT phosphorylation was examined
with an anti-phospho-AKT (p-AKT) antibody. Relative fold-change of p-AKT was determined
by densitometry analysis.
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AMPK and TSC2 are not required for adenovirus-induced autophagy. In order to verify that
AMPK phosphorylation does not contribute to adenovirus-mediated autophagy, we infected
AMPKα1 wild-type (AMPK wt) and knock-out (AMPK -/-) mouse embryonic fibroblasts
(MEF cells) with AdWT for 48 h. Consistent with the results we obtained from the array,
adenovirus infection in AMPK wt and AMPK -/- MEF cells induced an equivalent degree of
autophagy. Conversion of LC3-I to the lipidated and membrane-bound LC3-II was observed
48h after infection in both cell lines, irrespective of AMPKα1 expression (Figure 8A). This
data indicates AMPKα1 expression is not required for autophagy in adenovirus infected cells.
During starvation-induced autophagy, AMPKs initiate autophagy through phosphorylation of
TSC2 (Inoki et al., 2003; Inoki et al., 2002).Therefore we utilized RNAi technology to knockdown TSC2 in U251 glioma cells followed by infection with AdWT adenovirus for 48h
(Figure 8B). Again using LC3-I to LC3-II conversion as a marker, autophagy was observed
48h after infection in all cell lines, regardless of TSC2 expression status (Figure 8C). Thus, in
our system, the archetypal pathway that triggers starvation-induced autophagy was likely not
responsible for the dramatic induction of autophagy observed in adenovirus-infected cells.
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Figure 8. Adenovirus-mediated autophagy does not require expression of AMPKα
α1 or
TSC2. A, AMPKα1 wild-type and knock-out MEFs were treated with UV-inactivated or active
AdWT at an MOI of 100 for 48 h. Cell lysates were analyzed by western blot for conversion of
LC3-I to LC3-II, a marker of autophagy. B, TSC2 expression was inhibited by short-hairpin
RNA oligonucleotides in U251 glioma cells for 48h. C, Parental cells and cells transfected with
non-coding or TSC2 short hairpin RNAs were infected with ∆24RGD at an MOI of 10 for 48 h.
Western blot analysis was performed to detect LC3 conversion.
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Conclusions:

Divergent from starvation- and stress-induced autophagy, adenovirus-induced
autophagy does not require the activation of AMPKs or TSC2. Conversely, adenovirus
infection triggers the phosphorylation of inhibitory components of the autophagy signaling
pathway, AKT, mTOR and p70S6K. Our counterintuitive results were in contradiction with the
accepted tenet of molecular events that characterizes starvation-related autophagy (Noda and
Ohsumi, 1998; Inoki et al., 2002; Inoki et al., 2003; Kim et al., 2011), and immediately
suggested that adenoviruses utilize an alternative pathway in order to initiate autophagy that is
able to surmount the autophagy inhibitory effects of an activated AKT/mTOR pathway.
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Chapter IV: C-Jun N-terminal kinases are activated during adenovirus infection.

Rationale and Expectations:
JNK is a mitogen-activated kinase (MAPK) involved in numerous cellular processes,
including autophagy. Recent studies on starvation- and ceramide-induced autophagy
demonstrated that one isoform of the c-Jun N-terminal kinase (JNK) family, JNK1, positively
regulates autophagy (Wei et al., 2008; Pattingre et al., 2009). In addition, JNK kinases may
play a role in the regulation of ER stress-induced autophagy and oxidative stress-induced
autophagy (Ogata et al., 2006; Wong et al., 2010), as well as in the shift from autophagy to
autophagic cell death (Shimizu et al., 2010).
Importantly, there is evidence regarding JNK activation during adenovirus infection.
JNK is activated by the interaction of adenoviral fiber with the coxsackie adenovirus receptor
during adenoviral attachment to respiratory cells (Tamanini et al., 2003; Tamanini et al., 2006).
Moreover, JNK is an important effector of the anti-adenoviral immune response. Upon
replication of adenoviral DNA and transcription of adenoviral RNAs, cellular receptors (e.g.,
TLR9) and proteins (e.g., Rig-1) recognize the foreign oligonucleotides and stimulate JNK
signaling for expression of pro-inflammatory cytokines (Ichijo H., 1999; Johnson and Lapadat,
2002; Barton and Medzhitov, 2003; Minamitani et al., 2011). Furthermore, adenovirus-infected
cells characteristically express and release type 1 interferons at high levels via JNK-dependent
and independent pathways (Basner-Tschakarjan et al., 2006; Minamitani et al., 2011).
Interferons are also potent activators of JNK signal transduction leading to apoptosis (Ichijo et
al., 1997; Caraglia et al., 1999; Sung et al, 2001; Takada et al., 2005). The canonical
interleukin response to adenovirus also includes tumor necrosis factor-alpha, which can activate
JNK through Ask-1 signaling (Sung et al., 2001; Nishitoh et al., 1998; Yoon et al., 2008). In
addition to the possible cellular response to adenoviral infection, adenoviral proteins may
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directly interact with MAPK kinases (MAPKK) 5 or 7 to trigger JNK phosphorylation (See and
Shi, 1998). Therefore, JNK activation in adenovirus-infected cells may result from a multimechanistic process involving redundant activators from the cellular and viral repertoire.
Although a role for JNK in adenovirus-induced autophagy was not previously reported,
we hypothesized JNKs would be the critical component of a complex network that regulates
autophagy during adenovirus infection. Importantly, we expected JNK activation to occur not
only in adenovirus-infected healthy cells as previously described, but also in cancer cells
infected with the oncolytic, tropism-enhanced ∆24RGD adenovirus.
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Results:

JNK and c-Jun are phosphorylated during adenoviral infection. The Human Phospho-Kinase
Antibody Array (RandD Systems) encompassed many mitogen activated kinases (MAPK),
including those of the JNK pathway. We assessed the levels of phosphorylated JNK and the
downstream transcription factor c-Jun. Phosphorylation of both JNK and c-Jun increased
during adenoviral infection (Figure 9A,B). As early as 16h after infection, there was a ~3.5-fold
increase in the levels of phosphorylated JNK. In agreement with JNK activation, its
downstream target, c-Jun, maintained a ~4.5-fold increase when compared to the basal levels
observed in mock-infected cells (Figure 9B). However, JNK was phosphorylated in a timedependent manner, and peaked at a 35-fold increase in phospho-JNK levels 48 h after
adenoviral infection (Figure 9A). ERK1/2 are MAPK that often cross-talk with JNK signaling
(Johnson and Lapadat, 2002). Interestingly, modifications in the phosphorylation of ERK1 and
ERK2 were not evident at any point after adenoviral infection, thereby suggesting some degree
of specificity in the adenovirus-mediated activation of MAPKs (Figure 9B).

JNK pathway components are phosphorylated in adenovirus-infected cancer cells. We
confirmed the data obtained from the antibody array via western blot analyses of JNK and cJun phosphorylation in U87 malignant glioma (MG) cells (Figure 10A), A549 lung carcinoma
cells (Figure 10B), and HeLa cervical carcinoma cells (Figure 10C) infected with wild-type
adenovirus (AdWT) and/or ∆24RGD. In U87 MG cells, we detected phosphorylation of JNK
and the downstream transcription factor c-Jun 24 h after adenoviral infection. The levels were
comparable to those detected in cells treated with anisomycin, a chemical activator of JNK
phosphorylation (Kyriakis et al., 1994). As expected, the tropism enhanced ∆24RGD
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Figure 9. Adenovirus infection induces phosphorylation of c-Jun N-terminal kinases
(JNK) and their substrate, c-Jun. A, Phosphorylated protein levels of JNK (T183/Y185,
T221/Y223), ERK1/2 (T202/Y204, T185/Y187) and B, c-Jun (S63) were measured in wholecell protein lysates from AdWT-infected MCR5 cells using the Human Phospho-Kinase
Antibody Array. Cells were infected with an MOI of 50 for indicated time-points. Fold-increase
in phosphorylated protein levels was determined by densitometry analysis of the antibody
array. Values are an average of the spots in duplicate displayed on the bottom.

- 39 -

Figure 10. Wild-type and ∆24RGD
adenovirus replication activates the JNK signaling
∆
pathway in host cells. A, U87 MG cells were infected with UV-inactivated (UVi) or active
AdWT or ∆24RGD at an MOI of 50. B, A549 lung carcinoma cells were infected with UVi or
active AdWT at an MOI of 25. C, HeLa cervical carcinoma cells were infected with UVi or
active AdWT or ∆24RGD at an MOI of 25. Western blotting was performed on whole-cell
lysates for detection of phosphorylated JNK pathway proteins. Anisomycin (5 µM, 30 min) was
used as a positive control for JNK pathway activation.
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adenovirus (Fueyo et al., 2000; Fueyo et al., 2003) induced phosphorylation of JNK and c-Jun
to a greater degree than did AdWT at corresponding doses (Figure 10A). Similar results were
obtained with A549 lung carcinoma cells (Figure 10C). A time-course experiment in HeLa
cells confirmed that JNK was phosphorylated as early as 6 h after infection with AdWT or
∆24RGD. JNK phosphorylation increased drastically over time without exhibiting changes in
the level of total JNK protein expression (Figure 10B). Phosphorylated c-Jun was also detected
6h after adenoviral infection and increased over time. Phosphorylation of JNK pathway
components occurred concurrently with expression of the adenoviral protein E1A (Figure
10B,C). Importantly, UV-inactivated adenoviruses that are replication-incompetent did not
trigger JNK or c-Jun phosphorylation. Taken together, these data indicate that the JNK
signaling pathway is activated during adenoviral infection.

Infected glioma cells exhibit JNK phosphorylation in vivo. In order to corroborate the in vitro
data and determine the physiological relevance of our data, we sought to ascertain whether
adenoviral infection is followed by JNK phosphorylation in human glioma xenografts infected
with ∆24RGD. To this end, we examined the brains of U87 glioma-bearing nude mice injected
intratumorally with 107 plaque-forming units of ∆24RGD. JNK phosphorylation was detected
in the tumors infected with ∆24RGD (Figure 11, middle panels). Immunofluorescent
examination of viral and phospho-JNK proteins under a deconvolution microscope revealed the
co-localization of phospho-JNK (green fluorescence) with the adenoviral coat protein hexon
(red fluorescence). Importantly, we observed the nuclear localization of JNK during adenoviral
infection, which is required for JNK-mediated activation of transcription factors, including cJun (Kyriakis et al., 1994). As expected, neither phospho-JNK nor adenoviral hexon could be
detected in the adjacent healthy brain tissue (Figure 11, bottom panels); the recombinant
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Figure 11. Human glioma xenografts infected with ∆24RGD exhibit JNK
5
phosphorylation. U87 MG cells (10 ) were implanted intracranially in nude mice, and infected
7
intratumorally with 10 plaque forming units (pfu) ∆24RGD. Brain sections were imbedded in
paraffin and mounted on slides. Antibodies for phospho-JNK (green fluorescence) and hexon
(red fluorescence) were used to detect infected cells undergoing JNK activation. DAPI (blue
fluorescence) was used as a nuclear stain. Deconvolution microscopy was employed to
visualize brain tissue from 4 mice per treatment. The experiment was repeated twice with
mounted tissue sections from each animal. Representative images of the central tumor from
mice mock infected with PBS (top panel) or infected with ∆24RGD (middle panel) are
depicted. Images of the uninfected healthy brain tissue (bottom panel) surrounding the
∆24RGD-infected tumor cells are also included.
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∆24RGD adenovirus cannot replicate in healthy cells with an intact Rb pathway (Fueyo et al.,
2000; Fueyo et al., 2003). Phospho-JNK was also not detected in tumor or normal brain tissues
of mice treated with PBS vehicle alone (Figure 11, top panels).
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Conclusions:
JNK and the downstream constituent c-Jun were phosphorylated in adenovirus-infected
cells. JNK activation appeared to be ubiquitous; we demonstrated that immortalized, healthy
fibroblasts, malignant gliomas, cervical carcinoma cells, and lung carcinoma cells exhibited
JNK phosphorylation during adenovirus infection with either the wild-type adenovirus or the
genetically-modified, oncolytic ∆24RGD adenovirus. We established that JNK phosphorylation
occurred in ∆24RGD-infected glioma xenografts, indicating our data was not a product of the
in vitro culture conditions. Importantly, our data revealed in vitro and in vivo that JNK pathway
activation is replication-dependent suggesting interactions between adenoviral coat proteins
and cellular receptors during internalization is likely not the cause.
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Chapter V. JNK regulates Bcl-2 phosphorylation during adenovirus-mediated autophagy.

Rational and Expectations:
Bcl-2 is a negative regulator of autophagy due to its mitigating interaction with beclin 1,
which attenuates the formation of beclin1 complexes in the isolation membrane during
autophagy initiation (Figure 3) (Kihara et al., 2001; Pattingre et al., 2005; Levine et al., 2008).
Importantly, under starvation conditions JNK1-dependent phosphorylation of Bcl-2 suffices to
dissociate Bcl-2/beclin 1 heterodimers and thus allows autophagy to proceed (Wei et al., 2008).
Ceramide treatment also follows this same paradigm (Pattingre et al., 2009). Additionally,
evidence shows artificial activation of RNase L by 2'-5' linked oligoadenylates formed during
viral double stranded RNA recognition induces JNK-dependent Bcl-2 phosphorylation
(Siddiqui et al., 2012).
There is no previous study on the phosphorylation status of mammalian Bcl-2 in cells
infected with adenovirus. The nature of JNK-mediated phosphorylation of Bcl-2 remains under
investigation and has not yet been specifically addressed in adenovirus-induced autophagy;
however, we expect that the JNK activation we observed during adenovirus infection would
result in Bcl-2 phosphorylation that would coincide with the release of beclin 1 and activation
of autophagy.
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Results:

Bcl-2 is phosphorylated in adenovirus-infected cells undergoing autophagy. In order to
ascertain the role of JNK and Bcl-2 during adenovirus-mediated autophagy, we first needed to
assess Bcl-2 phosphorylation in adenovirus-infected cells. Using western blotting techniques,
we detected Bcl-2 phosphorylation as early as 24h after infection with AdWT or ∆24RGD
adenovirus in U87 MG (Figure 12A), HeLa cervical carcinoma, (Figure 12B) as well as A549
lung carcinoma cells modified to stably over-express mammalian Bcl-2 (a generous gift of Tim
McDonnell, M.D. Anderson Cancer Center) (Figure 12C). Phosphorylation of Bcl-2 increased
consistently and reproducibly in all three cell lines 48 h after infection (Figure 12A-C). In U87
cells, phospho-Bcl-2 levels reached a 20-fold increase 48 h after adenoviral infection (Figure
12A), comparable to the positive control Paclitaxol. Relevant to our hypothesis, we observed
JNK and Bcl-2 phosphorylation were events parallel to the induction and development of
autophagy. Thus, western blot analyses revealed a remarkable conversion of LC3-I to lipidated,
membrane bound LC3-II after adenoviral infection in all cancer cell lines examined (Figure
12A-C). These data strongly indicated that JNK pathway activation and Bcl-2 phosphorylation
coincide with the formation of autophagosomes (Kabeya et al., 2000).

Glioma xenografts infected with ∆24RGD express phosphorylated Bcl-2. Next, we assessed
physiological relevance of this phenomenon in human glioma xenografts treated with ∆24RGD
adenovirus (Figure 13). Analogous to JNK, Bcl-2 was also phosphorylated (red fluorescence)
in cells that concomitantly expressed the adenoviral coat protein hexon (green fluorescence).
Unlike phospho-JNK, which is found in both the nucleus and cytoplasm of infected cells,
phosphorylated Bcl-2 was localized to the cytoplasm as expected (Figure 13). Furthermore,
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Figure 12. Wild-type and ∆24RGD adenovirus infection induces B-cell lymphoma 2 (Bcl2) phosphorylation. A, U87 MG cells were infected with UVi or active ∆24RGD adenovirus at
an MOI of 50 and protein lysates were analyzed via western blot. B, HeLa cells were infected
with UVi or active AdWT adenovirus at an MOI of 25. Cell lysates were prepared in IP lysis
buffer, and incubated with antibodies to Bcl-2. Immunoprecipitated complexes and input (5%)
samples were analyzed by western blot. C, A549 cells were stably transfected to express
increased levels of Bcl-2. Cells were then infected with UVi or active AdWT adenovirus at an
MOI of 25 and protein lysates examined by western blot.
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Figure 13. Malignant gliomas infected with ∆24RGD exhibit Bcl-2 phosphorylation. U87
5
7
MG cells (10 ) were implanted intracranially in nude mice, and infected intratumorally with 10
pfu ∆24RGD. Brain sections were imbedded in paraffin and mounted on slides. Antibodies for
phospho-Bcl-2 (red fluorescence) and hexon (green fluorescence) were used to detect infected
cells undergoing JNK activation. DAPI (blue fluorescence) was used as a nuclear stain.
Deconvolution microscopy was employed to visualize brain tissue from 4 mice per treatment.
The experiment was repeated twice with mounted tissue sections from each animal.
Representative images of the central tumor from mice mock infected with PBS (top panel) or
infected with ∆24RGD (middle panel) are depicted. Images of the uninfected healthy brain
tissue (bottom panel) surrounding the ∆24RGD-infected tumor cells are also included.
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meticulous examination of the tumor and adjacent brain tissue of the ∆24RGD-infected,
glioma-bearing mice revealed that Bcl-2 was phosphorylated in infected tumors but not in the
normal brain tissue (Figure 13). As expected, neither tumor nor normal brain tissues obtained
from mice treated with the PBS vehicle alone exhibited Bcl-2 phosphorylation. These in vivo
results not only buttressed the validity and reproducibility of the in vitro observations by
confirming and expanding our results, but also unequivocally demonstrated that JNK and Bcl-2
phosphorylation in adenovirus-infected cells was not an artifact of the in vitro culture
conditions.

Adenovirus-induced Bcl-2 phosphorylation is JNK-dependent. Previous studies (Wei et al.,
2008; Pattingre et al., 2009; Siddiqui et al., 2012) and our data suggested a functional
regulation of Bcl-2 by JNK. We used isogenic MEF cells to determine the extent to which JNK
expression is required for Bcl-2 phosphorylation. We obtained MEF cells that were wild-type
for JNK (JNK wt) and MEF cells lacking both JNK1 and JNK2 genes (JNK1/2 -/-). Of note,
JNK3 is expressed at low levels in JNK wt and JNK1/2 -/- cell lines (Figure 15). In agreement
with our previous observations, Bcl-2 phosphorylation increased dramatically in wild-type
MEF cells infected with AdWT (Figure 14A). Conversely, infection of JNK1/2 -/- MEF cells
did not induce an increase in Bcl-2 phosphorylation (Figure 14A). To determine the effect of
JNK activation on Bcl-2 phosphorylation, we used a chemical inhibitor (SP600125) to prevent
JNK phosphorylation in adenovirus-infected A549 lung carcinoma cells. Pre-treatment of cells
with 25 µM SP600125 completely prevented Bcl-2 phosphorylation after infection with AdWT
for 48 h (Figure 14B). Importantly, SP600125 inhibits the phosphorylation of all three JNK
isoforms: JNK1, JNK2, and JNK3.

- 49 -

Figure 14. Adenovirus-induced Bcl-2 phosphorylation requires JNK expression and
activation. A, Wild-type and JNK1/2 DKO (JNK1/2 -/-) MEFs were infected with UVinactivated or active AdWT adenovirus at an MOI of 100. Protein lysates were prepared in IP
lysis buffer and incubated with antibodies to Bcl-2. Immunoprecipitated complexes and input
(5%) samples were analyzed by western blot. B, A549 cells were stably transfected to express
increased levels of Bcl-2, and treated with DMSO or SP600125 (25 µM) for 30 min prior to
infection with AdWT at an MOI of 25 for 48 h. Whole-cell lysates were prepared and analyzed
via western blot for Bcl-2 phosphorylation. Relative fold change in phospho-Bcl-2 was
determined by densitometry analysis.
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Figure 15. Several cell lines, including JNK1/2 DKO cells, express low levels of JNK3.
Whole cell lysates from mouse brain, HeLa cells, U87 MG cells, and wild-type and JNK1/2 -/MEF cells were analyzed by western blot for the expression of JNK3.
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Knock-out of both JNK1 and JNK2 is required to inhibit Bcl-2/beclin 1 dissociation. We
utilized additional isogenic MEF cells to determine the extent to which the isoforms JNK1 and
JNK2 were required for eliciting the resultant dissociation of Bcl-2/beclin 1 protein complexes
after Bcl-2 phosphorylation (Wei et al., 2008; Pattingre et al., 2009). We performed an
immunoprecipitation assay to detect beclin 1 bound to Bcl-2. As expected, wild-type MEF cells
exhibited a decrease in Bcl-2/beclin 1 complexes after infection with AdWT adenovirus
(Figure 16). Importantly, we were also able to detect dissociation of beclin 1 from Bcl-2 in
infected MEF cells lacking either JNK1 (JNK1 -/-) or JNK2 (JNK2 -/-). In contrast, adenoviral
infection did not disrupt Bcl-2/beclin 1 heterodimers in JNK1/2 -/- MEF cells (Figure 16). To
our knowledge, these data are the first demonstration that elimination of both JNK1 and JNK2
is required to inhibit adenovirus-mediated Bcl-2 phosphorylation and subsequent modulation of
beclin 1 interactions.
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Figure 16. Knock-out of both JNK1 and JNK2 isoforms blocks the dissociation of Bcl2/beclin 1 complex and induction of autophagy by adenovirus. Wild-type, JNK1 KO (JNK1
-/-), JNK2 KO (JNK2 -/-), and JNK1/2 DKO (JNK1/2 -/-) MEFs were infected with AdWT
adenovirus at an MOI of 100 for 48 h. Protein lysates were prepared in IP lysis buffer and
incubated with antibodies to Bcl-2. Both Bcl-2-immunoprecipitated and input (5%) samples
were analyzed via western blot for the interaction between beclin 1 and Bcl-2.
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Conclusions:
Our data clearly demonstrated JNK expression and activation regulates Bcl-2
phosphorylation during adenovirus infection. Similar to JNK, Bcl-2 was also phosphorylated in
infected tumors in vivo indicating that this pathway is functional in a whole system with
potential interactions from the surrounding microenvironment. In addition, JNK-mediated Bcl2 phosphorylation triggered dissociation of Bcl-2/beclin 1 heterodimers. Contrary to the
regulation involved in starvation-induced autophagy, knock-out of JNK1 alone was not able to
inhibit Bcl-2 phosphorylation or release of beclin 1. Indeed, JNK1 and JNK2 isoforms may
play redundant roles in Bcl-2-mediated regulation of beclin 1, because knock-out of both is
.required to inhibit the event. JNK3 likely has a negligible effect upon this pathway; despite
JNK3 being expressed in JNK1/2 double knock-out MEF cells, we were not able to detect an
increase in Bcl-2 phosphorylation or Bcl-2/beclin 1 dissociation. Thus, we discovered an
activated signaling pathway that has not been described previously in adenovirus-infected cells.
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Chapter VI. JNK regulates adenovirus-mediated autophagy.

Rational and Expectations:
The regulation of autophagy through activation of JNK is well-documented. JNKs play
a role in the regulation of ER stress-induced autophagy and oxidative stress-induced autophagy
(Ogata et al., 2006; Wong et al., 2010), as well as in the shift from autophagy to autophagic
cell death (Shimizu et al., 2010). The activation of JNK-dependent autophagy by cancer
chemotherapeutic agents is under investigation as well. JNK expression and activation is
required for autophagy induced by resveratrol, oridonin, and bufalin (Puissant et al., 2010; Cui
et al., 2007; Xei et al., 2011). Interestingly, JNK has been implicated in regulating autophagy
activated by insulin-like growth factor-1 and tumor necrosis factor-alpha signaling (Jia et al.,
2006). Recent studies on starvation-induced autophagy demonstrated that one isoform of the cJun N-terminal kinase (JNK) family, JNK1, positively regulates autophagy via phosphorylation
of Bcl-2 in order to dissociate Bcl-2/beclin 1 heterodimers and thus allows autophagy to
proceed (Wei et al., 2008). Ceramide treatment also follows this same paradigm (Pattingre et
al., 2009). In addition, artificial activation of RNase L by 2'-5' linked oligoadenylates formed
during viral double stranded RNA recognition has been shown to induce JNK-dependent Bcl-2
phosphorylation, Bcl-2/beclin 1 dissociation, and autophagy induction (Siddiqui et al., 2012).
Importantly, the molecular events that lead to JNK-dependent autophagy are not well
understood. Moreover, the biological significance of JNK-mediated autophagy differs among
various forms of stress.
Our data shows upon adenoviral infection, JNK phosphorylates Bcl-2 and is required
for the consequent dissociation of Bcl-2/beclin 1 complexes. Armed with our own and
previously documented results, we expected JNK expression and activation is required for
adenovirus-induced autophagy. We also anticipated JNK1 and JNK2 may have redundant roles
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due to the data we obtained in the isogenic MEF cells; thus, both must be knocked-down in
order to inhibit autophagy.
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Results:

JNK1 and JNK2 cooperate to stimulate autophagy in adenovirus-infected cells. We used the
isogenic MEF cell lines to further evaluate the requirement of JNK1 and/or JNK2 in regulating
adenovirus-mediated autophagy. JNK wt, JNK1 -/-, and JNK2 -/- MEF cells performed
productive autophagy after adenoviral infection, according to the marked degradation of p62
(Figure 17A). Remarkably, JNK1 alone was not required to induce adenovirus-dependent
autophagy. This finding again differs from the accepted paradigm for starvation-induced
autophagy (Wei et al., 2008). After adenoviral infection, knock-out of both JNK1 and JNK2
expression in the MEF cells was required to prevent p62 degradation (Figure 17A). In addition,
knock-out of c-Jun expression in MEF cells (c-Jun -/-) did not inhibit p62 degradation in
adenovirus-infected MEF cells, thereby suggesting JNK-dependent activation of transcription
through c-Jun is not required for adenovirus-mediated autophagy (Figure 17B). In order to
validate our data, we used the classical, most definitive method for detecting autophagy in
cells: visualization of autophagosomes via electron microscopy. JNK wt, JNK1 -/-, and JNK2 /- cells exhibited formation of abundant autophagic vacuoles (Figure 18A). A higher
magnification of these vacuoles proved that they were in fact the double-membrane–bound
vacuoles that are distinctive of autophagosomes (Figure 18B). On the contrary, the majority of
JNK1/2 -/- MEF cells infected with adenovirus did not contain autophagosomes (Figure 18A).
Upon meticulous examination and quantification of the infected cell population, 75% of
adenovirus-infected JNK wt cells were positive for autophagosomes. Double knock-out of
JNK1 and JNK2 isoforms resulted in greater than 50% reduction in the number of infected cells
containing autophagosomes (Figure 18C).
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Figure 17. Knock-out of both JNK1 and JNK2 isoforms, but not the substrate c-Jun,
prevents productive autophagy during adenovirus infection. A, Wild-type, JNK1-/-, JNK2 /-, and JNK1/2 -/- MEF cells were infected with UV-inactivated or active AdWT adenovirus at
an MOI of 100. Western blot was employed to analyze productive autophagy in whole cell
lysates using anti-p62 antibodies. B, C-Jun KO (c-Jun -/-) MEFs were infected with UVinactivated or active AdWT adenovirus at an MOI of 100.
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Figure 18. Knock-out of both JNK1 and JNK2 reduces autophagosome formation in
adenovirus-infected cells. A, Wild-type, JNK1-/-, JNK2 -/-, and JNK1/2 -/- MEF cells were
infected with UV-inactivated or active AdWT adenovirus at an MOI of 100 for 48h. Electron
microscopy was utilized to visualize the double-lipid-bilayer-bound autophagic vacuoles that
form during adenovirus-mediated autophagy. Images of whole cells(~6000X) and
corresponding higher magnification intracellular regions (~25000X) for each cell line were
collected to detect autophagosome formation. B, Representative high-magnification images of
autophagic vacuoles in wild-type, JNK1 -/- and JNK2-/- MEFs are included. C, The number of
wild-type and JNK1/2 -/- cells in infected samples was quantified manually from 5 fields (~45
cells total). The graph represents the percentage of cells that were positive for autophagy above
basal levels (>10 autophagosomes).
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JNK isoforms regulate autophagy in adenovirus-infected cancer cells. We substantiated the
results obtained in the isogenic MEF cell lines using small interfering RNAs (siRNA) that were
specific for the JNK1 and JNK2 isoforms to directly target and down-modulate JNK expression
in U87 MG cells. We were able to achieve approximately 80% knock-down of JNK isoforms
(as detected by a pan-JNK antibody). As expected, U87 MG cells expressing non-coding
siRNAs and infected with ∆24RGD adenovirus exhibited p62 degradation and LC3-I to LC3-II
conversion. Consistent with our previous results, simultaneous down-regulation of JNK1 and
JNK2 expression impaired adenovirus-mediated autophagy according to these markers (Figure
19).

JNK activation is required for adenovirus-mediated autophagy. JNK-mediated regulation of
Bcl-2/beclin 1 interactions was facilitated by adenovirus-triggered JNK phosphorylation. Thus,
JNK phosphorylation would be integral to the efficient regulation of autophagy in host cells.
To examine this hypothesis, A549 cells were pre-treated with a chemical inhibitor selective for
JNK phosphorylation, SP600125, prior to infection with adenovirus. We observed a decline in
the p62 protein levels, indicating p62 degradation, and conversion of LC3-I to LC3-II
suggesting productive autophagy occurred in A549 cells infected with adenovirus alone
(Figure 20A). However, when these cells were pre-treated with SP600125 to inhibit JNK
phosphorylation, autophagy was strikingly diminished (Figure 20A). These results suggest a
critical role for JNK and Bcl-2 in the biochemical machinery that directs adenovirus-mediated
autophagy. In order to determine the consistency of our data in various cell types and conclude
that these phenomena apply to the oncolytic, tropism-enhanced ∆24RGD, we assessed the
induction of autophagy after adenoviral infection in U87 MG cells (Figure 20B). Cells were
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Figure 19. RNA interference of JNK1 and JNK2 isoforms reduces adenovirus-mediated
autophagy. JNK1 and JNK2 expression was reduced by isoform-specific siRNA
oligonucleotides combined and introduced into U87 MG cells. Non-coding siRNAs were used
as controls. After 48 h, cells were infected with ∆24RGD adenovirus at an MOI of 50 for 36 h.
LC3 conversion was analyzed for productive autophagy. Relative fold-change in LC3-II was
determined by densitometry analysis.
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Figure 20. Chemically inhibiting JNK phosphorylation blocks adenovirus-associated
autophagy initiation. A, A549 cells were stably transfected to express increased levels of Bcl2. After pre-treatment with 25 µM SP600125 30 min, cells were infected with ∆24RGD
adenovirus at an MOI of 50 for 48 h. Western blotting was performed with whole cell protein
lysates to examine p62 degradation and LC3 conversion. B, U87 MG cells were transfected
with an EGFP-LC3 vector. After 48h, cells were pre-treated with DMSO or SP600125 (25 µM)
for 30 min prior to infection with ∆24RGD adenovirus at an MOI of 50 for 48h. GFP-LC3
puncta formation was visualized upon induction of autophagy. Representative deconvolution
microscopy images are depicted (left). C, The percentage of LC3-puncta positive cells (>10
puncta) was determined by counting the total cells in 5 fields from three independent
experiments. Statistical significance was determined using the Student’s t test (right).
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transfected to over-express exogenous GFP-LC3. Under normal conditions, the GFP-LC3 was
expressed ubiquitously throughout the cell. However, upon infection with adenovirus, the
characteristic GFP-LC3 puncta formation indicates LC3-II insertion into the membrane of
autophagic vacuoles. We observed this phenomenon in greater than 65% of the cells infected
with ∆24RGD adenovirus, thereby confirming autophagy (Figure 20B). Importantly, GFP-LC3
puncta formation was impaired in the majority of cells pre-treated with SP600125. Thus, the
number of cells positive for autophagy was significantly reduced in cells pre-treated the JNK
inhibitor (Figure 20B).
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Conclusions:
Our study yields new information about the biological significance of JNK pathway
activation in adenovirus-mediated autophagy. Phosphorylation of both JNK and Bcl-2 was
detected in vitro and in vivo upon adenovirus infection. Furthermore, expression and activation
of JNK was required for Bcl-2 phosphorylation, release of Beclin 1, and the consequent
induction of autophagy. Contrary to starvation which is dependent solely on JNK1, ablation of
both JNK1 and JNK2 was required to inhibit adenovirus-mediated autophagy. In addition,
knock-out of c-Jun expression did not inhibit p62 degradation in adenovirus-infected MEF
cells, thereby suggesting JNK-dependent modifications in Bcl-2 phosphorylation regulate
autophagy instead of JNK-dependent modification in transcription through c-Jun. We did not
focus our studies on JNK3 because this isoform is expressed primarily in neurons and the heart
(Martin et al., 1996; Gupta et al., 1996; Kuan et al., 1999). In agreement with this, although
JNK3 was expressed at low levels in JNK1/2 -/- MEF cells (Figure 15), these cells were not
able to undergoing productive autophagy. Thus, JNK3 likely has negligible effects upon
adenovirus-induced autophagy based on the data we obtained. Our data suggested adenoviruses
can utilize diverse host cell pathways to obtain their ultimate goal of cell lysis, and proposed a
novel role for JNK2 in the regulation of autophagy that had not been described previously.
Comprehending the mechanistic regulation of autophagy in response to adenovirus infection
should provide the opportunity to assess prospective targets for combined chemotherapeutic
strategies with the ∆24RGD adenovirus currently in a phase 1 clinical trial for the treatment of
recurring malignant gliomas.
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Chapter VII: JNK and autophagy facilitate presentation of adenoviral antigens.

Rationale and Expectations:
JNK has various roles within the cellular immune response machinery against viral
infection. Cellular proteins (e.g. TLR9, Rig-1, OAS) recognize viral DNA and RNA and
stimulate signaling through JNK for the expression of pro-inflammatory cytokines. (Ichijo H.,
1999; Johnson and Lapadat, 2002; Barton and Medzhitov, 2003; Minamitani et al., 2011).
JNK pathway activation leads to expression and release of type 1 interferons, which are also
powerful inducers of JNK signal transduction (Ichijo et al., 1997; Caraglia et al., 1999; Sung
et al, 2001; Takada et al., 2005; Basner-Tschakarjan et al., 2006; Minamitani et al., 2011).
However, there is a paucity of information regarding the role of JNK in the presentation of
antigens and has not yet been investigated within the context of adenoviruses or autophagy.
Autophagy is a well-documented mechanism of immune presentation of viral antigens
(Figure 4). In addition to the direct sequestration and degradation of viruses, autophagy
participates in the processing of antigens for presentation in major histocompatibility (MHC)
molecules on the surface of infected cells (Crotzer and Blum, 2009; English et al. 2009;
Paludan et al, 2005). Autophagy has been implicated in the processing of viral antigens
primarily for presentation on MHC class II molecules (Münz et al., 2000; Paludan et al., 2005;
Jaraquemada et al., 1990). Importantly, whether autophagy is required for the presentation of
adenovirus antigens has not yet been examined. Thus, we hypothesized that adenovirusmediated autophagy is an anti-viral immune response: initiated by immune-related receptors,
transduced by the JNK MAP kinase pathway, and concluded with the presentation of
adenoviral epitopes to the immune system for further recruitment and activation of immune
cells. We expected that JNK and autophagy would be essential to the display of adenoviral
antigens at the surface of host cells; and thus, the consequent activation of immune cells.
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Results:

JNK is essential to the display of adenoviral antigens at the cell surface. In order to test our
hypothesis, we designed an experiment to detect a variety of adenoviral epitopes on the surface
of intact, live cells after infection for 48 hours. After using an antibody cocktail against several
capsid antigens, we identified cells displaying adenoviral antigens by addition of fluorescent
secondary antibodies and detection via flow cytometry. We observed greater than 13% of wildtype MEF cells presented adenoviral antigens on the cell membrane after infection with AdWT
(Figure 21). In contrast, the percentage of JNK1/2 -/- MEF cells presenting adenoviral antigens
was hardly detectable (~2%). The mitigating effects of knocking-out JNK1 and JNK2 gene
expression on the presentation of adenoviral eptiopes to the immune system were significant (p
< 0.001) (Figure 21). Thus, JNK expression is required for efficient adenoviral antigen
presentation.

JNK regulates adenoviral antigen presentation for the activation of immune cells. Next, we
verified that the display of adenoviral antigens on ∆24RGD-infected wild-type MEF cells could
activate primed splenocytes; thus, confirming adenoviral epitopes are being presented by MHC
molecules for activation of immune cells. Splenocytes were isolated from naïve and ∆24RGDimmunized C57BL/6 mice, and then combined in culture with pre-infected JNK wt and JNK1/2
-/- MEF cells. After 24 h of co-culture, we detected IFNγ in the culture medium as a welldescribed marker of splenocyte activation (Figure 22A). Only the wild-type MEF cells preinfected with ∆24RGD were able to dramatically stimulate IFNγ production in splenocytes
from immunized mice (primed) (Figure 22B). The MEF cells lacking JNK1 and JNK2 genes
were deficient in activating the primed splenocytes; thus, ~75% less IFNγ was detected in the
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Figure 21. JNK regulates the display of adenoviral antigens at the surface of host cells. A,
Wild-type and JNK1/2 -/- MEF cells were infected with AdWT adenovirus at an MOI of 100
for 48 h. Live cells were incubated with antibodies raised against a blend of adenoviral coat
proteins. The cells were subsequently stained with APC-conjugated secondary antibodies and
analyzed via flow cytometry. Mouse IgG was used as a control and propidium iodide was used
to eliminate dead cells. The percentage of cells that display adenoviral coat antigens at the
surface of the cell is represented in the graph. Statistical significance was determined using the
Student’s t test.
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Figure 22. Adenovirus-infected MEF cells require JNK expression in order to activate
splenocytes from immunized mice. A, A schematic of the protocol detecting splenocyte
7

activation is depicted. In brief, C57BL/6 mice were infected with 10 pfu ∆24RGD adenovirus
twice (Day 1 and 3) intracranially through a guide-screw method. The animals were euthanized
on Day 14 and spleens were collected. In parallel, wild-type and JNK1/2 -/- cells were infected
with an MOI of 100 for 24 h. Splenocytes from naïve and immunized mice were then cocultured with the pre-infected MEFs for 24 h. The levels IFNγ in the co-culture medium was
detected using the Mouse IFN gamma ELISA kit. B, The graph represents the concentration of
IFNγ (pg/ml) in the co-culture media, which is indicative of splenocyte activation. Statistical
significance was determined using the Student’s t test.
- 70 -

culture medium of these cells (Figure 22B). Importantly, neither JNK wt nor JNK1/2 -/- preinfected with ∆24RGD could provoke IFNγ production in naïve splenocytes. In addition, mock
infected JNK wt and JNK1/2 -/- could not stimulate primed splenocytes. This confirms the
IFNγ is produced by the primed splenocytes only upon activation by infected cells that can
efficiently present adenoviral antigens.

Adenoviral antigens are processed and presented on MHC class II molecules. It remains
elusive the extent to which adenoviral antigens are presented on MHC class I or MHC class II
molecules and the role of JNK in this process. Thus, we infected JNK wt and JNK1/2 -/- MEF
cells with ∆24RGD and incubated them with blocking antibodies against MHC class I or MHC
class II. Splenocytes from ∆24RGD-immunized C57BL/6 mice were then added for 24 hours
and IFNγ production was detected in the co-cultured media as an indicator of splenocyte
activation (Figure 23A). We detected a 30-fold increase in splenocyte activation by preinfected JNK wt MEF cells without blocking antibodies or with IgG (Figure 23B). Again, the
JNK1/2 -/- cells exhibited a considerably deficient ability to activate splenocytes. Importantly,
a significant decrease in IFNγ production was detected from splenocytes in co-culture with preinfected JNK wt and MHC class II blocking antibodies (Figure 23B). Conversely, splenocyte
activation was not appreciably inhibited by MHC class I blocking antibodies. Therefore, our
data suggest adenoviral antigens are presented on MHC class II molecules in a JNK-dependent
manner.

JNK-dependent autophagy is a mechanism of viral antigen processing. The data we collected
in MEF cell lines were reproducible in U87 MG cells infected with ∆24RGD adenovirus in
combination with the inhibitor of JNK phosphorylation, SP600125. After infection with
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Figure 23. MHC class II-dependent adenoviral antigen presentation activates splenocytes
from immunized mice. A, A schematic of the protocol detecting splenocyte activation is
7

depicted. C57BL/6 mice were infected with 10 pfu ∆24RGD adenovirus intracranially.
Spleens were isolated on Day 14. In parallel, wild-type and JNK1/2 -/- MEFs were infected
with an MOI of 100 for 24 h. The cells were washed and incubated with blocking antibodies to
MHC class I or MHC class II molecules. IgG was used as a control. After 2 h, splenocytes from
immunized mice were added for co-culture with the pre-infected MEFs and blocking antibodies
for 24 h. The levels IFNγ in the co-culture medium was detected using the Mouse IFN gamma
ELISA kit. B, The concentration of IFNγ (pg/ml) in the co-culture media is displayed
graphically. Statistical significance was determined using the Student’s t test.
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Figure 24. JNK activation and autophagy regulate the presentation of adenoviral antigens
on cancer cells. U87 MG cells were pre-treated with DMSO, SP600125 (25 µM), or
bafilomycin A1 (10 nM) for 30 min prior to infection with ∆24RGD adenovirus at an MOI of
50 for 48 h. Live cells were incubated with a combination of antibodies raised against a blend
of adenoviral coat proteins. Upon staining with an APC-conjugated secondary antibody, cells
were analyzed by flow cytometry. A mouse IgG was included as a control, and dead cells were
excluded by propidium iodide staining. APC-positive cells were quantified (upper right) and
analyzed for statistical significance. Infected samples pre-treated with inhibitors were
compared to those pre-treated with DMSO. Asterisks (*) indicate a pvalue of less than 0.05
determined by a Student’s t test.
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∆24RGD for 48 h, approximately 19% of cells displayed adenoviral capsid epitopes at their
surface. A significant decrease (p = 0.02) in the number of cells presenting adenoviral antigens
was observed after adenoviral infection was combined with the SP600125 inhibitor (Figure
24). We next examined the effect on antigen presentation caused by blocking the autophagy
flux.

In these studies, we used bafilomycin A1 (BA1), a well-characterized inhibitor of

autophagy which prevents the fusion of autophagosomes with lysosomes (Yamamoto et al.,
1998). As expected, this halted the processing of antigens. We observed that the number of
cells pre-treated with 10 nM BA1 that displayed adenoviral epitopes at the surface decreased
significantly (Figure 24). Collectively, these data strongly suggest that both JNK and JNKregulated autophagy are part of the cellular processes leading to the efficient processing and
presentation of adenoviral antigens in cells infected with adenoviruses.

Rapamycin enhances adenoviral antigen presentation. Rapamycin activates autophagy
through chemical inhibition of mTOR (Brown et al., 1994; Noda and Ohsumi, 1998). We
combined treatment with rapamycin and infection with ∆24RGD adenovirus in order to
determine the effect of combining an autophagy-promoter on adenoviral antigen presentation.
After co-treatment for 48 hours, there was a significant increase in the display of adenoviral
epitopes at the surface of U87 MG cells. Approximately 65% of cells presented adenoviral
antigens after combination therapy, which was a 2-fold increase when compared to ∆24RGD
alone (Figure 25). Our data confirm rapamycin enhances adenoviral antigen presentation and
corroborate our discovery that autophagy regulates this process.

Autophagy degrades viral proteins for antigen presentation on the surface of cells. Self and
foreign proteins are degraded in autophagosomes in order to recycle basic components, as well
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Figure 25. Rapamycin enhances adenoviral antigen presentation. U87 MG cells were pretreated with 100 nMrapamycin, an activator autophagy via mTOR inhibition. After 30 min,
cells were infected with ∆24RGD at an MOI of 50 for 48 h. Cells were incubated with
antibodies to a blend of adenoviral coat proteins followed by staining with APC-conjugated
secondary antibodies. Live, APC-positive cells were detected by flow cytometry; dead cells
were excluded by propidium iodide staining. The percentage of antigen-presenting cells are
represented in the graph and compared for statistical significance using a Student’s t test.
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as to present peptides within MHC molecules at the surface of the cell for detection by the
immune system (Klionsky et al., 2000; Crotzerand Blum, 2009; English et al., 2009; Paludan
et al., 2005; Levine et al., 2011). Notably, autophagy-related protein 5 (Atg5) is required for
the activation and maintenance of autophagy induced by various stimuli including adenovirus
(Mizushima et al., 1998; Jiang et al., 2011). Thus, we used isogenic MEF cell lines in order to
examine the role of autophagy in the degradation and presentation of adenoviral antigens to the
immune system. First, we examined the ability for these isogenic cell lines to display
adenoviral antigens on the cell surface. The data obtained in adenovirus-infected malignant
glioma cells pre-treated with bafilomycin A1 (Figure 24) was confirmed in Atg5 -/- cells.
While wild-type MEF cells presented adenoviral antigens on their surface (~15%), Atg5-/- cells
displayed significantly less (p < 0.01) adenoviral epitopes (Figure 26). Next, we examined the
protein levels of adenoviral fiber in wild-type Atg5 (Atg5 wt) and Atg5 knock-out (Atg5-/-)
MEF cells via western blot. In agreement with the accepted paradigm of autophagy, we
detected considerably less adenoviral fiber protein in Atg5 wt cells when compared to the
levels of fiber in Atg5 -/- cells (Figure 27A). This data suggests that fiber is being degraded
during productive autophagy in wild-type MEF cells, and this phenomenon is inhibited in the
autophagy-deficient Atg5 -/- MEF cells. In agreement with this data, we discovered that p62, a
chaperone protein selectively degraded in autophagosomes, binds to adenoviral fiber and hexon
proteins in Atg5 wt and Atg5-/- cells (Figure 27B). Again, the protein levels of p62-bound fiber
and hexon were much higher in the Atg5 knock-out cells. Of note, we confirmed that cells
expressing wild-type Atg5 were able to undergo autophagy after adenoviral infection by
detection of LC3-I to LC3-II conversion; however, the Atg5 knock-out MEF cells did not
exhibit this marker (Figure 27B). Additionally, we used isogenic p62 MEF cells to confirm the
role of p62 in the recruitment of adenoviral proteins for degradation and antigen presentation.
Wild-type p62 MEF cells were able to present adenoviral antigens similar to the Atg5 wt cells.
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Figure 26. Autophagy regulates the display of adenoviral epitopes at the surface of cells.
A, Wild-type and Atg5 KO (Atg5-/-) MEF cells were infected with AdWT adenovirus at an
MOI of 100 for 48 h. Live cells were incubated with a combination of antibodies raised against
a blend of adenoviral coat proteins. After staining with APC-conjugated secondary antibodies,
the cells were analyzed via flow cytometry. Mouse IgG was used as a control, and propidium
iodide was used to exclude dead cells. B, The graph depicts the percentage of cells presenting
adenoviral antigens. Statistical significance was determined using the Student’s t test.
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Figure 27. P62 binds to adenoviral coat proteins for degradation and antigen presentation
through autophagy. A, Wild-type and Atg5 KO (Atg5-/-) MEF cells were infected with AdWT
adenovirus at an MOI of 50 for indicated times. Whole cell protein lysates were analyzed by
western blot for adenoviral fiber expression. B, Wild-type and Atg5 -/- MEF cells were
infected with AdWT adenovirus at an MOI of 50 and cell lysates were prepared in IP lysis
buffer. Lysates were incubated with antibodies to p62. Both p62-immunoprecipitated
complexes and input (5%) samples were analyzed by western blotting for adenoviral hexon and
fiber protein expression. C, Wild-type and p62 KO (p62 -/-) MEF cells were infected with
AdWT adenovirus at an MOI of 100 for 48 h. Live cells were incubated with a blend of
antibodies raised against adenoviral coat proteins. APC-conjugated secondary antibodies were
used to examine cells by flow cytometry. Mouse IgG was used as a control, and propidium
iodide was used to exclude dead cells. The percentage of cells that display adenoviral coat
antigens is indicated at the top right corner of the histogram. Statistical significance was
determined using the Student’s t test.
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There was a highly significant decrease in the number of cells displaying adenoviral epitopes
when p62 was genetically knocked-out (p62 -/-) (Figure 27C). Interestingly, the inhibition of
adenoviral antigen presentation in p62 -/- MEF cells (Figure 27C) was not as dramatic in Atg5
-/- MEF cells (Figure 26), suggesting other chaperone proteins may be involved in the
recruitment of adenoviral antigens, such as heat shock proteins (Dice, 2007). Taken together,
our data suggests p62 may assist in the targeting of adenoviral proteins for degradation in
autophagosomes resulting in the presentation of adenoviral antigens to the immune system.
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Conclusions:
Here, we establish for the first time that infected cells present adenoviral antigens
through the process of autophagy. In addition, our novel data clearly demonstrates JNK
regulates adenoviral antigen presentation, possibly by autophagy-dependent and -independent
mechanisms. Importantly, we confirm that the activation of immune cells by infected cells is
dependent upon JNK-mediated adenoviral antigen presentation. Similar to other viruses that
induce autophagy (Münz et al., 2000; Paludan et al., 2005; Jaraquemada et al., 1990), our data
suggests adenoviruses also present antigens on MHC class II molecules at the cell surface.
However, this is likely that adenoviral antigen presentation is both MHC class I- and MHC
class II-dependent. We also observe autophagy-dependent p62 recruitment and consequent
degradation of viral capsid proteins for presentation at the cell surface. As autophagy primarily
degrades proteins and loads peptides onto MHC class II molecules for presentation, our results
further establish the role of autophagy in adenoviral antigen presentation. Moreover,
augmenting adenovirus-mediated autophagy through rapamycin-induced mTOR inhibition was
able to drastically enhance the display of adenoviral antigens, which is significant to the
development of adenoviral-based immunotherapeutic and combination strategies.
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Chapter VIII: Delta-24-FvIII infection induces EGFRviii antigen presentation.

Rationale and Expectations:
Modulating the immune system using conditionally replicating, oncolytic adenoviruses
is under investigation for the targeted treatment of cancer (Bridle et al, 2010). Evidence
suggests recombinant adenoviruses expressing tumor-associated antigens can prime the
environment for an immune response against tumor cells (Chen et al., 1996; Rosenberg et al.,
1998; Perricone et al., 2000; Sorensen et al., 2009). The first FDA-approved therapeutic
cancer vaccine Provenge (Sipuleucel-T) activates patient’s immune cells by professional
antigen presentation of prostatic acid phosphatase (PAP), which is selectively over-expressed in
most prostate cancer cells. Provenge is currently being used for the treatment of castrationresistant prostate cancer (Huber et al, 2012).
Epidermal growth factor receptor (EGFR) is frequently up-regulated in cancer,
particularly malignant gliomas, and the EGFR variant III (EGFRvIII) is an extremely prevalent,
tumor-specific mutation (Moscatello et al., 1995). It is also a highly immunogenic protein;
thus, it is considered a tumor-associated antigen that can be used in the development of
immunotherapeutic approaches (Sampson et al., 2009). Our laboratory has previously
investigated the efficacy of targeting EGFRvIII-expressing malignant gliomas (Piao et al.,
2009); however, using recombinant adenoviruses to harness and reprogram the immune system
to attack EGFRvIII-expressing tumor cells has yet to be investigated. We hypothesized that an
adenovirus expressing the immunogenic EGFRvIII epitope would prime immune cells against
tumor cells which endogenously over-express this molecule. Specifically, we expected infected
tumor cells will present the EGFRvIII antigen to the immune system by autophagy-dependent
mechanisms that could be enhanced by stimulating the cellular immune response.
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Results:

The cancer-specific antigen, EGFRvIII, was inserted into adenoviral fiber to form a novel

∆24FvIII adenovirus. Our data suggested that adenoviral fiber is recruited to autophagosomes
by p62 and then degraded into peptides which are presented on the surface of cells. Thus, we
developed an EGFRvIII-expressing, anti-tumor vaccine (termed ∆24FvIII) that encompasses a
chimeric fiber protein with incorporation of the immunogenic EGFRvIII epitope
(LEEKKGNYVVT; Sampson et al., 2009) in the HI-loop (Figure 28A). The 24-base pair
deletion in the E1A gene sequence is included in order to enforce selective replication of the
adenovirus in Rb-inactivated tumor cells, similar to the ∆24RGD adenovirus (Fueyo et al.,
2001; Fueyo et al., 2003). We established the successful insertion of the EGFRvIII peptide into
the adenoviral fiber sequence by direct DNA sequencing, and western blot using a monoclonal
antibody that was raised against this epitope specifically (termed L8A4). Our data indicates
A549 cells infected with the novel ∆24FvIII adenovirus expressed high levels of the EGFRvIII
peptide (Figure 28B). These cells did not express EGFRvIII endogenously or after infection
with the ∆24 adenovirus lacking the EGFRvIII peptide. Furthermore, a mobility shift was
visualized when detecting adenoviral fiber protein by western blotting, suggesting an increase
in molecular weight caused by the insertion of the EGFRvIII epitope (Figure 28B).

Infection with ∆24FvIII adenovirus results in presentation of the EGFRvIII antigen. We
next examined the presentation of this peptide on the surface of infected cells, and the role of
autophagy in this system. Wild-type and Atg5-/- MEF cells were infected in parallel with the
∆24FvIII adenovirus. In concordance with our previous data, the Atg5 wt MEF cells displayed
EGFRvIII epitopes on the cell surface. We detected ~62% of Atg5 wt cells displayed the
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Figure 28. An immunogenic EGFRvIII epitope is inserted in the HI loop of the ∆24
adenovirus fiber sequence. A, The EGFRvIII epitope (LEEKKGNYVVT) was inserted into
the HI loop of the ∆24 adenovirus fiber sequence by excision exonucleases as indicated by the
schematic illustration. The novel oncolytic adenovirus ∆24FvIII was rescued in HEK293 cells.
B, Expression of the chimeric fiber encompassing the EGFRvIII peptide was examined in A549
cells infected with ∆24FvIII at an MOI of 40 for 48 h. Protein lysates were analyzed by western
blot analysis using anti-adenoviral fiber or a monoclonal antibody (termed L8A4) raised against
this specific EGFRvIII epitope.
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Figure 29. ∆24FvIII infection induces presentation of the ectopic EGFRvIII antigen. Wildtype and Atg5 -/- MEFs were infected with ∆24FvIII at an MOI 100 for 48 h. Live cells were
first incubated with the monoclonal EGFRvIII antibody L8A4, followed by staining with FITCconjugated secondary antibodies and analysis by flow cytometry. Mouse IgG was used as a
control and propidium iodide staining was used to exclude dead cells. The percentage of cells
displaying the EGFRvIII epitope is indicated at the top right corner of each histogram. The
difference between infected wild-type and infected Atg5 -/- cells was statistically significant as
determined by a Student’s t test. Asterisks (***) indicate a p value of less than 0.001.
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tumor-associated EGFRvIII epitope on the cell surface (Figure 29). Due to the specificity of
the L8A4 antibody, the percentage of cells we detected presenting EGFRvIII antigens is much
higher than the percentage of cells we detected using non-specific antibodies to a blend of
adenoviral epitopes. Importantly, we observed a highly significant decrease in the percentage of
Atg5-/- MEF cells displaying EGFRvIII antigens (Figure 29). Additionally, HeLa cells infected
with this adenovirus also exhibited EGFRvIII antigen presentation that was ablated upon
inhibiting autophagy with bafilomycin A1 (BA1) (Figure 30, upper panel). To further illustrate
the role of autophagy in presenting this antigen to the immune system, we combined interferon
gamma (INFγ) treatment with ∆24FvIII infection to enhance the expression of MHC molecules
within host cells. Interferon gamma dramatically increased the presentation of EGFRvIII
epitopes on the surface of HeLa cells, when compared to cells either mock infected or infected
with ∆24FvIII alone (Figure 30, lower panel). Importantly, the effects of both interferon and
adenoviral-mediated autophagy were blocked by bafilomycin A1, suggesting autophagy plays a
critical role in presenting foreign antigens in the cellular immune response to adenovirus. Our
data also indicates the competence of the ∆24FvIII adenovirus as an anti-tumor vaccine by its
innate ability to induce autophagy for the presentation of this immunogenic EGFRvIII epitope
on cancer cells.
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Figure 30. Bafilomycin A inhibits adenovirus-induced and IFNγγ-enhanced antigen
presentation. HeLa cells were infected with ∆24FvIII at an MOI of 40. After infection for 6 h,
300 units/ml of INFγ was added to the cells. Bafilomycin A1 (BA1; 100 nM) was added to the
culture 24 h post infection. Live cells were collected 48 h after infection and incubated with the
L8A4 monoclonal antibody for EGFRvIII. Staining with FITC-conjugated secondary
antibodies was followed by analysis via flow cytometry. Propidium iodide staining excluded
dead cells. The graph represents the percentage of cells presenting EGFRvIII epitopes.
Statistical significance between indicated samples was determined by a Student’s t test and is
represented by asterisks: (**) indicates a p value of less than 0.01, while (*) indicates a p value
of less than 0.05.
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Conclusions:
We constructed a novel adenovirus expressing the immunogenic EGFRvIII epitope
within the HI loop of adenoviral fiber protein in order to 1) confirm the data we obtained
detecting antigen presentation of a blend of adenoviral capsid proteins using non-specific
antibodies, and 2) develop an adenovirus that presents the tumor-associated EGFRvIII antigen
on the surface of infected tumor cells; and thus, has the potential to initiate an anti-tumor
immune response. We succeeded in detecting the display of EGFRvIII antigens on the host cell
surface during infection with the ∆24FvIII adenovirus. In accordance with previous data, this
phenomenon was prevented by bafilomycin A1, confirming the role of autophagy in the
presentation of adenoviral-expressed antigens. Interestingly, IFNγ was able to enhance the
display of EGFRvIII antigens, probably due to increased MHC class II expression (Giroux et
al., 2003). However, bafilomycin A1 was also able to inhibit IFNγ-enhanced adenoviral antigen
presentation suggesting once again that autophagy controls the presentation of adenoviral
antigens on MHC class II molecules. Importantly, the data we collected previously showing
activation of immune cells by ∆24RGD-infected MEF cells strongly supports that immune cells
can be activated against the EGFRvIII antigen. Future experimentation will focus on the extent
to which the EGFRvIII-targeted immune cells can elicit an anti-tumor immune response.
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Chapter IX: List of Conclusions (Figure 31)
1. Adenovirus infection does not activate autophagy through the archetypal pathway
regulating starvation- and stress-induced autophagy.
a. AMPKs are not appreciably phosphorylated and are not required for adenovirusmediated autophagy
b. TSC2 is not required for adenovirus-induced autophagy.
c. AKT and mTOR are highly phosphorylated, but fail to inhibit autophagy
2. JNK pathway is active in cells infected with adenovirus.
a. JNK and c-Jun are phosphorylated in numerous cell types and after infection
with either wild-type or ∆24RGD adenovirus.
b. JNK is phosphorylated in vivo.
3. JNK phosphorylates Bcl-2 resulting in dissociation of Bcl-2/beclin 1 complexes.
a. Bcl-2 is phosphorylated in vitro and in vivo.
b. JNK expression and activation are required for adenovirus-induced Bcl-2
phosphorylation.
c. JNK1 and JNK2 regulate the dissociation of Bcl-2/beclin 1 heterodimers.
4. JNK is essential to the induction of autophagy in adenovirus-infected cells.
a. JNK expression and activation is required for adenovirus-induced autophagy.
b. JNK1 and JNK2 have potentially over-lapping roles in the regulation of
adenovirus-induced autophagy.
c. JNK activation regulates the loss in cell viability of adenovirus-infected cells.
5. JNK and autophagy regulate adenoviral antigen presentation.
a. JNK expression is essential to the display of adenoviral antigens at the host cell
surface and consequent activation of immune cells.
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b. Adenoviral antigens are presented on MHC class II molecules.
c. Autophagy regulates the presentation of adenoviral antigens.
d. P62 recruits adenoviral proteins, particularly fiber, to autophagosomes for
degradation into peptides.
6. EGFRvIII antigens are presented on the surface of ∆24FvIII infected cells.
a. An immunogenic EGFRvIII peptide is inserted into the HI loop of the
adenoviral fiber sequence.
b. The EGFRvIII epitope is expressed and presented on the surface of ∆24FvIII
infected cells.
c. Inhibiting

autophagy

prevents

presentation of EGFRvIII antigens.
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∆24FvIII-induced

and

IFNγ-enhanced

Figure 31. The role of JNK and autophagy in the adenoviral antigen presentation.
Adenoviruses infect and replicate within the cell triggering JNK phosphorylation. JNK
phosphorylates Bcl-2 resulting in the release of beclin 1, a key activator of autophagy. P62
binds to adenoviral proteins being produced within the cell and recruits them to
autophagosomes for degradation into peptides. Autophagosomes fuse with the MHC class II
compartment (MIIC). Peptides are loaded onto MHC class II molecules for antigen
presentation. Activators of this pathway (rapamycin or IFNγ) amplify antigen presentation. The
∆24FvIII adenovirus infection results in presentation of EGFRvIII cancer-specific antigens.
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Chapter X: Discussion
Herein, we demonstrated a unique mechanism underlying the regulation of autophagy in
adenovirus-infected cells. We utilized a wild-type adenovirus as well as a tumor-selective,
oncolytic adenovirus termed ∆24RGD, which is currently in clinical testing for the targeted
treatment of malignant brain tumors (Fueyo et al., 2003; Jiang et al., 2007). We infected a
series of normal and cancer human cell lines and genetically engineered mouse embryo
fibroblasts. In doing so, we established that adenoviral replication in host cells induced strong
and sustained activation of the JNK signal transduction pathway that is required for adenovirusinduced autophagy. We also show that activation of JNK is required for the autophagy-related
processing of adenovirus antigens and their presentation on the cell surface. We believe that in
the fullness of time these results may have important overtones for the development of
adenovirus-based vaccines for infectious diseases and cancer.
We initially sought to validate the preliminary data on recombinant adenoviruses
reported by Ito and collaborators for our model system: glioma cells infected with a tropismenhanced adenovirus (Ito et al., 2006). They suggested that adenoviral infection is followed by
the hypo-phosphorylation of mTOR 72 hours after infection, thus inducing autophagy (Ito et
al., 2006). In this pioneer study, Ito and colleagues may be observing a decrease of mTOR
phosphorylation during the host cell lysis. At this late stage, the expression and
phosphorylation of proteins is irrelevant to explain cellular events that occur prior to cell death.
Our present experiments and previous studies (Jiang et al., 2007; Jiang et al., 2011) showed
that autophagy is detectable in cells as early as 36 hours after infection with adenoviruses. In
this study, a time-dependent examination of AKT and mTOR phosphorylation showed that the
AKT/mTOR pathway was activated 16 hours after infection with wild-type and ∆24RGD
adenoviruses, and this activation was maintained up to 48 hours. We also did not observe
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activation of AMPK, a common cause of mTOR inactivation in cells undergoing autophagy
(Inoki et al., 2003; Kim et al., 2011; Codogno and Meijer, 2005). Furthermore, we showed that
AMPK and TSC2 expression are not required for adenovirus-mediated initiation of autophagy.
Thus, in our system, this archetypal pathway was likely not responsible for the dramatic
induction of autophagy in adenovirus-infected cells.
Our data showed that JNK activation was extremely amplified during adenoviral
replication. Importantly, no noticeable change in the phosphorylation of other MAP kinases
(e.g. ERK1/2) was observed, suggesting specificity. For the first time, we demonstrate Bcl-2 is
phosphorylated during adenovirus infection, and that JNK is required for Bcl-2 phosphorylation
in adenovirus-infected cells. In contrast to the accepted tenet of molecular events regulating
starvation-induced autophagy (Wei et al., 2008), Bcl-2/beclin 1 complexes are deregulated by
the activation of either JNK1 or JNK2 during adenovirus infection. It was also intriguing to see
that both JNK1 and JNK2 proteins played a role in the adenovirus-mediated induction of
autophagy, and that complete ablation of both isoforms was required to block autophagy
initiation. These data suggest that JNK1 and JNK2 have overlapping roles in the regulation of
adenovirus-mediated autophagy. Our results further differentiate adenovirus-induced autophagy
from starvation-induced autophagy, and suggest that their activation of JNK is probably
regulated at multiple levels with complex overlapping mechanisms.
We initially hypothesized that adenoviral proteins activate JNK1 and JNK2 through
interactions with upstream constituents of this signaling pathway in the host cell. According to
a previous report, the adenoviral protein E1B-19K may directly interact with MAPK kinases
MAPKK5 or MAPKK7 to trigger JNK phosphorylation (See and Shi, 1998). This preliminary
study examined the phosphorylation of a downstream substrate of JNK, c-Jun, during
adenovirus infection in the presence and absence of E1B-19K. However, c-Jun has been
identified as the target of many MAP kinases such as ERK1/2 and p38 (Leppä et al., 1998;
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Yamagishi et al., 2001); therefore, their data regarding the role of E1B-19K in adenovirusinduced JNK activation remain inconclusive. Our attempts to corroborate these preliminary
findings using specific antibodies to detect JNK phosphorylation during adenovirus infection in
the presence and absence of E1B-19K were unsuccessful (data not shown). Furthermore, we
infected cells with adenoviruses mutant for each individual early gene and discovered no single
protein is required for activation of JNK during adenovirus infection. JNK activation was only
prevented during infection with viruses lacking the E1A gene sequence (data not shown), which
is required for all viral DNA replication, transcription and protein expression (Nevins et al.,
1979; Bayley and Mymryk, 1994). Ectopic over-expression of individual adenoviral proteins by
plasmid transfection was also ineffective at activating endogenous JNK (data not shown).
In addition, our laboratory examined several other potential stimuli regulating
adenovirus-induced JNK activation. Adenoviruses, JNK, and autophagy are all involved in
numerous, and often overlapping, stress-response pathways (e.g. ER stress, DNA damage,
oxidative stress). First, we investigated key constituents of the ER stress response during
adenovirus infection. We found little to no change in the phosphorylation of protein kinase
RNA-like endoplasmic reticulum kinase (PERK) or inositol-requiring protein 1 (IRE-1) (data
not shown), which are previously described activators of JNK during ER stress (Urano et al.,
2000; Nishitoh et al., 2002). Next, we examined the role of DNA damage response in
adenovirus-induced JNK activation (Cuconati et al., 2003). Although we detected the markers
of DNA damage, gamma histone 2AX (γH2AX) and phosphorylated Ataxia telangiectasia
mutated (ATM) protein kinase, neither of these proteins were required for JNK activation
during adenovirus infection (data not shown). Lastly, upon combining the antioxidant N-acetyl
cysteine (Aggarwal et al., 2011) with adenovirus infection, we discovered reducing oxidative
stress has no effect on JNK activation in infected cells (data not shown). Thus, although we
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cannot completely rule out any of these pathways possibly linking adenovirus infection and
JNK activation, the data we have collected suggests JNK is activated within host cells by other
mechanisms.
Upon discovering the role of JNK in antigen presentation, we hypothesized that
adenovirus-mediated activation of JNK may be part of the innate immune response against the
virus. Cellular receptors (e.g., TLR9) and proteins (e.g., Rig-1, OAS) are known to recognize
adenoviral oligonucleotides in order to stimulate JNK-dependent transcription of proinflammatory cytokines, including type 1 interferons (Ichijo H., 1999; Johnson and Lapadat,
2002; Barton and Medzhitov, 2003; Basner-Tschakarjan et al, 2006; Minamitani et al., 2011).
Type 1 interferons can also activate JNK signal transduction in an attempt to eradicate the
infected cell by inducing apoptosis (Ichijo et al., 1997; Caraglia et al., 1999; Sung et al, 2001;
Takada et al., 2005); although, adenoviruses have numerous mechanisms for blocking
apoptosis downstream of JNK (Rao et al., 1992; White, 1993). Additionally, type 1 interferons
lead to the up-regulation of 2′,5′-oligoadenylate synthetase (OAS) (Rutherford et al., 1988).
OAS can recognize adenoviral double stranded RNAs and produces 2'-5' linked oligoadenylates
which trigger activation of RNase L (Hovanessian et al., 1977, Zhou et al., 1993). Interestingly,
artificial activation of RNase L by 2'-5' linked oligoadenylates has recently been shown to
induce JNK-dependent Bcl-2 phosphorylation, Bcl-2/beclin 1 dissociation, and autophagy
induction (Siddiqui et al., 2012). Therefore, JNK activation in adenovirus-infected cells may
result from a multi-mechanistic process involving redundant activators from the cellular and
viral repertoire that fight against and converge with the adenovirus initiative to control the host
cell and thereby generate a favorable scenario for its replication and spread. Further
investigation is required to determine the extent to which each of these pathways are involved
in activating JNK for the purpose of inducing autophagy and antigen presentation.
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Autophagy promotes cell lysis; and thus, is advantageous for the adenovirus (Jiang et
al., 2011). However, it is a double-edged sword; as JNK-mediated autophagy also benefits the
host through promotion of adenoviral antigen-presentation and consequent activation of
immune cells against the virus. Although autophagy has been well-documented in adenovirusinfected cells, its role in this specific scenario is not completely understood. For some RNA
viruses, autophagosomes are “viral factories”; thus, autophagy is employed in the interest of
virus survival (Wileman, 2006). This paradigm cannot be applied to adenoviruses which, unlike
RNA viruses, are assembled in the nucleus (D'Halluin, 1995), and are thus physically distant
from cytoplasmic autophagosomes. Autophagy is a critical pathway for the processing of
antigens and facilitating their interaction with MHC molecules (Crotzer and Blum, 2009;
Orvedahl and Levine, 2009; Lin et al., 2010). During autophagy, proteins are digested to
generate peptides of the required length and with the required modification in the N terminus to
bind MHC class II complexes (Paludan et al., 2005). In macrophages infected with herpes
simplex virus type 1, autophagy facilitates the presentation of viral antigens in MHC class II
molecules on the cell membrane (English et al., 2009). In agreement with this information, our
data suggests adenoviral antigens are also processed via autophagy for presentation on MHC
class II molecules at the cell surface.
Our finding that adenovirus-infected cancer cells induce JNK/autophagy-dependent
antigen presentation to the immune system is a significant one. Understanding this process
resulted in the construction of a recombinant adenovirus encompassing an immunogenic
peptide inserted in the adenoviral fiber protein sequence, the ∆24FvIII adenovirus. We
demonstrated that ectopic expression of an EGFRvIII tumor-associated antigen by the
adenovirus will lead to its display at the cell surface. Future research will examine the extent to
which this virus induces an anti-tumor, particularly an anti-glioma, immune response in animal
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models and in patients. Furthermore, future experimentation should include combinations of
chemical stimulators of autophagy (rapamycin) with recombinant adenoviruses expressing
cancer-specific antigens for enhanced tumor vaccination. Rapamycin was able to drastically
enhance the display of adenoviral antigens, potentially through mTOR inhibition and
consequent autophagy induction (Brown et al., 1994; Noda and Ohsumi, 1998). This small
molecule inhibitor is under clinical investigation for the treatment of malignant gliomas alone
and in combination with other chemical inhibitors of the AKT/mTOR pathway (Chang et al.,
2004; Galanis et al., 2005; Goudar et al., 2005; Reardon et al., 2010). Moreover, our
laboratory has shown rapamycin combined with the ∆24RGD adenovirus enhances the in situ
oncolytic effects (Alonso et al., 2008). Thus, there are implications for both oncolytic
virotherapy and vaccine-based immunotherapy in combination with this compound to improve
the clinical outcome of patients suffering from malignant gliomas.
Adenoviruses have the innate ability to recruit immune cells to the site of infection
(Tatsis et al., 2004). Treatment with targeted, oncolytic adenoviruses has the potential to
directly lyse tumor cells as well as instigate a localized immune response at the site of the
tumor (Jiang et al., 2007; Jiang et al., 2011; Jager et al., 2003). Designing recombinant
adenoviruses expressing tumor-associated antigens enhances their prospective recognition by
immune cells and consequent anti-tumor immunity (Rosenberg et al., 1998; Bendandi et al.,
1999; Gulley et al., 2002). Due to the mutability of the adenoviral genome, this therapeutic
approach can easily be adapted to personalized medicine. Using the antigen expression profile
of each patient’s tumor, we can administer a combination of recombinant adenoviruses
expressing tumor-associated antigens that could increase the probability of positive clinical
outcomes.
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It is essential to understand the molecular events regulating adenovirus-induced cell
lysis, as well as how the host cell triggers an antiviral immune response, so that we may
leverage these pathways in the development of novel anti-cancer vaccines. The targeted,
EGFRvIII-expressing adenovirus is a product of the information discovered by this
investigation. It capitalizes upon the inherent network of interactions between the virus and
host cell machinery. It has the potential to trigger an immune response against malignant
gliomas in a high percentage of patients. This unique immunotherapeutic strategy aims to
improve the currently fatal prognosis of malignant gliomas.
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